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An estimated 200,000 injuries to the anterior cruciate ligament (ACL) occur 
annually in the United States, with approximately 100,000 total ACL reconstructions 
performed each year. Due to inherent limitations with existing ACL reconstruction 
strategies, the development of tissue engineered ligaments is a key area of 
musculoskeletal research. Although great strides have been made in the scaffold design, 
current strategies are limited by the inability to replicate the mechanical behavior of 
native ligament tissue with synthetic polyesters or natural polymers. Poly(ester 
urethane)s have recently been investigated as possible scaffold materials because of their 
established biocompatibility, excellent mechanical properties, and exceptionally tunable 
structure. However, non-specific degradation makes it difficult to tailor polyurethane 
structure to complement ligament regeneration. In contrast, a biomaterial that features            
system-responsive degradation would integrate with native ligament remodeling and 
thus provide effective load transfer to newly formed tissue that is necessary to restore 
mechanical integrity. 
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In this study, enzyme-labile peptide sequences were conjugated to ether-based 
polyols to form collagen-mimetic soft segments that feature cell-responsive degradation. 
Synthetic routes were first developed to functionalize these polyols with favorable end 
groups for peptide coupling. Upon successful conjugation, biodegradable soft segments 
were then incorporated into the structure of linear polyurea elastomers. By varying soft 
segment chemistry, soft segment molecular weight, and the hard to soft segment ratio, a 
library of cell-responsive, biodegradable polyureas was developed. This library can then 
be used to elucidate key structure-property relationships necessary to complement 
neotissue formation. Overall, synthesis of a novel biomaterial that combines the strength 
and tunability of synthetic elastomers with cell-responsive degradation will assist in the 
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1.1  Overview 
Orthopaedic conditions have an enormous impact on quality of life and remain 
one of the leading reasons that patients seek medical care. In particular, musculoskeletal 
injuries comprise more than 14 percent of the health care dollar in the United States.1 A 
significant portion of these injuries result from ligament and tendon damage. The 
anterior cruciate ligament (ACL) is the most commonly injured ligament of the knee 
with over 200,000 Americans requiring reconstructive surgery in 2002 at an associated 
medical cost exceeding five billion dollars.2, 3  
The ACL is the major intra-articular ligament of the knee that connects the 
posterior-lateral part of the femur to the anterior-medial part of the tibia. It provides 
necessary joint stabilization for normal kinematics and prevents excessive anterior 
translation of the femur that could result in dislocation, bone fracture, or cartilage 
damage.4 Damage to the ACL results in pain, loss of mobility, joint instability, and can 
eventually lead to injury of other tissues and the development of degenerative joint 
diseases, such as osteoarthritis.5-7 After rupture, angiogenesis does not occur within the 
ACL for approximately 12 weeks.8 As a result, damaged ACL tissue lacks significant 
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inhibiting its natural regeneration.9-11 The intrinsic properties of ACL-derived cells also 
play a role in its inadequate healing capacity.12-16 ACL fibroblasts exhibit inferior 
proliferation, migration, and responses to growth factors than fibroblast derived from the 
medial collateral ligament (MCL), and in response to injury, ACL fibroblasts 
demonstrate limited growth factor expression and lower upregulation of collagen type 
III, which has been shown to facilitate scar tissue formation.12-17 The inability of 
damaged ACL tissue to heal post injury necessitates surgical intervention. Despite the 
large number of ligament reconstructions performed each year, an ideal grafting material 
has yet to be developed.10, 11 
1.2  Current Ligament Reconstruction 
1.2.1 Autografts 
Current surgical techniques available for ACL reconstruction include 
transplantation of autografts, allografts, and synthetic grafts.4, 10, 11, 18-22 Despite inherent 
limitations, the use of tendon autografts has been recognized as the “gold standard” of 
ACL repair.18, 23, 24 During reconstructive surgery, the surgeon harvests a portion of the 
patient’s patellar, hamstring, or quadriceps tendon to serve as a replacement ligament.25, 
26
 The patellar tendon graft is explanted with a piece of bone from the patella and one 
from the insertion point at the tibia.4 This “bone-patellar-bone” graft is then inserted 
through a tunnel drilled through the tibia, stretched across the knee, and attached 
through a tunnel drilled into the femur. The “bone-patellar-bone” graft has high initial 
graft strength, and because it has a bone plug on each end, it can incorporate quickly 
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with either fixation site. This allows for earlier motion of the knee and a shorter period 
of rehabilitation.27  
Hamstring autografts are typically harvested from the semitendinosus and 
gracilis tendons, which are then braided and folded over to strengthen the graft. 
Advantages of a hamstring tendon graft include a smaller incision, less anterior knee 
pain, and a thicker tendinous portion within the knee joint.18 Furthermore, despite 
removing two of the three medial muscular stabilizers of the knee, the hamstring retains 
most of its functionality.18 The quadriceps tendon autograft is usually harvested from the 
central portion of the quadriceps with a bone plug from the proximal end of the patella 
to provide articular fixation. The major disadvantage of this technique is that the size 
and location of the donor-site scar can be problematic for the patient.  
In general, autografts typically possess good initial mechanical strength and 
promote cell proliferation, and they are conducive to graft remodeling and integration 
into the joint.24, 27-29 Despite these advantages, the use of autogenous grafts is limited. 
Their long-term success is dependent on revascularization of the transplanted tissue, 
which is progressively surrounded by the synovial membrane.8, 30 The availability of 
autogenous grafts can be an issue, whether due to the need for multiple surgeries or 
age.26, 31 Finally, donor site pain, muscle atrophy, and tendonitis can lead to prolonged 






To circumvent problems associated with autogeneic tendon grafts, the use of 
allografts has been employed for ACL repair. Allografts are tissues harvested from a 
cadaver, such as the patellar, hamstring, and achilles tendon, which eliminates the need 
for an additional surgical site.21, 33 This reduces surgical time and minimizes 
postoperative pain.31  Like autografts, allografts provide good initial mechanical strength 
and promote cell proliferation and remodeling, with the added benefit of an unlimited 
graft supply.24, 34 Nevertheless, there are still limitations to this therapy including disease 
transmission, bacterial infection, and unfavorable immunogenic responses.23, 35 Although 
sterilization and preservation can minimize these risks, they also reduce the tensile 
properties of the graft, limiting its use for ACL reconstruction.18, 31, 36-39 
1.2.3 Synthetic Grafts 
Due to the limitations of biologic grafts, synthetic materials have been 
investigated for potential use in ACL reconstruction.22, 40  These grafts do not require 
sacrifice of autogenous tissue and do not lose their strength due to tissue remodeling, 
which allows for much faster rehabilitation.41 Prostheses of homogenous,                  
non-degradable polymers evaluated for ACL repair include carbon fiber, the Gore-Tex 
ligament (polytetrafluoroethylene), the Stryker-Dacron and Leeds-Keio ligaments 
(polyethylene terephthalate), and the Kennedy Ligament Augmentation Device 
(polypropylene).10, 11, 22, 23, 30, 42-44 The Gore-Tex ligament is composed of a single, 
continuous fiber of expanded polytetrafluoroethylene (ePTFE) that is wound into 
multiple loops and joined together to form a braid.45 The Stryker-Dacron ligament 
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consists of a core of four tightly woven Dacron tapes encased by a sleeve of loosely 
woven Dacron velour, and it was designed to promote tissue ingrowth.21, 46 Similar to 
the Stryker-Dacron ligament, the Leeds-Keio ligament is composed of polyethylene 
terephthalate (PET) with an open-weave tube to promote ingrowth of fibrous tissue.47, 48 
Finally, the Kennedy Ligament Augmentation Device (LAD) is a cylindrical prosthesis 
with a diamond-braided construction, and it was designed for simultaneous implantation 
with a biologic graft to augment the tissue and protect it during the early stages of 
healing.49, 50 The Gore-Tex and Stryker-Dacron ligaments have each received general 
release from the Food and Drug Administration (FDA) as permanent ligament 
replacements, but only to salvage previously failed intra-articular reconstructions.31, 48 
Although these devices typically provide immediate stabilization of the joint, 
they are unable to duplicate the mechanical behavior of the ACL and eventually fail due 
to material fatigue.11, 31 Due to the high linear stiffness of synthetic implants, a majority 
of the physiological load is borne by the prosthesis, effectively stress shielding the 
surrounding tissue.4, 11, 51, 52 Without proper mechanical cues to direct collagen alignment 
and tissue organization, the load-bearing capacity of the native tissue is reduced so that 
the synthetic graft is limited to its inherent fatigue properties. In addition to graft 
rupture, repeated elongation of these devices can lead to permanent deformation at 
points of stress, which results in a loosening of the ligament and a loss of joint 
stabilization.53, 54 Contact with sharp edges of the bone tunnels can also cause abrasions 
that weaken the implant and create debris, which can elicit an unfavorable foreign body 
response.11, 55 Woven prostheses face additional challenges such as axial splitting, low 
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extensibility, low tissue infiltration, and abrasive wear that can lead to synovitis in the 
joint.4, 10, 11, 51, 52, 56 Long-term studies have also revealed a high incidence of 
osteoarthritis post implantation.7, 54 Overall, the limitations of current ACL 
reconstruction strategies present a substantial margin for improvement in the escalating 
market for ACL repair. 
1.3  Anterior Cruciate Ligament Tissue Engineering 
 Musculoskeletal tissue engineering has received growing interest throughout 
orthopedic medicine as a promising alternative to biologic and synthetic grafts.4, 30, 57, 58 
Tissue engineers attempt to harness the body’s natural ability to repair and regenerate 
damaged tissue through the application of biological, chemical, and engineering 
principles. This strategy can potentially improve upon current clinical options by 
providing appropriate biological and mechanical properties to regenerate damaged ACL 
tissue without the aforementioned limitations of other grafts.4, 10, 11, 19 ACL 
reconstruction utilizing a tissue-engineered ligament would eliminate donor site pain and 
morbidity, improve and accelerate rehabilitation, provide a limitless supply of graft 
tissue, eliminate the risk of disease transmission or unfavorable immunogenic responses, 
and increase the fatigue life of the graft.10, 11 
 The traditional tissue engineering paradigm combines isolated cells and bioactive 
factors on a biodegradable scaffold that sustains functionality during tissue regeneration 
and serves as a structural template for neotissue formation, Figure 1.1.10, 11, 19, 59 In 
ligament constructs, scaffolds are seeded with fibroblasts or mesenchymal stem cells 
that are then provided with the necessary mechanical and biochemical cues to initiate 
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ligament regeneration. To facilitate this process, the biomaterial selected for these 
constructs must be biocompatible, biodegradable, and permit typical cell-material 
interactions necessary for cell proliferation, migration, and differentiation. The scaffold 
must also demonstrate interconnected porosity to enable nutrient transport, waste 
removal, and tissue infiltration. Finally, the tissue engineered construct must 
demonstrate appropriate mechanical behavior to maintain functionality throughout 
native tissue remodeling. The need to duplicate the complex function and unique 
mechanical properties of the ACL at all stages of remodeling is partly responsible for the 
difficulty encountered in developing a suitable surgical replacement. Therefore, 
advancement of ligament tissue engineering strategies is strongly dependent on the 
ability of tissue engineers to develop a biomaterial scaffold that reproduces both the 
mechanical and physiologic properties of native ACL tissue.  
 
 
Figure 1.1. Traditional tissue engineering paradigm. 
 
Knowledge of ligament structure and its components is extremely important in 
the development of a scaffold for ligament tissue engineering. Interactions among such 
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components and their arrangement in the tissue give ligaments their unique mechanical 
properties.4 The ACL is predominantly composed of collagen, elastin, proteoglycans, 
glycoproteins, water, and fibroblasts.4, 60 Fibroblasts not only synthesize fibrillar 
collagen but also enzymatically break down and remove old collagen as part of native 
tissue remodeling. Synthesis of collagen makes up roughly 80% of all protein synthesis 
in the ACL, with a ratio of type I collagen to type III collagen at approximately 88% to 
12%, respectively.61, 62 Type I collagen forms tough, nonelastic cross-linked fibers that 
contribute to the tensile strength of ligaments and tendons.60, 62 Type III collagen forms 
loosely organized, thin fibrils that provide elasticity.60, 62 Type I collagen molecules 
form a hierarchical structure of dense, highly organized, cable-like tissue in which fiber 
bundles orient parallel to the longitudinal axis in a helical formation.4, 10, 11, 61, 63 
Fibroblasts align between these collagen bundles and elongate in the direction of 
loading.61 Fiber bundles form a periodic crimp pattern that permits 7 to 16% creep 
before permanent deformation or ligament damage can occur. Overall, it is this complex, 
hierarchical structure that dictates the bulk tensile properties of the ACL. 
The mechanical and viscoelastic properties of the human ACL have been      
well-documented. The human ACL is regularly exposed to cyclic loads as high as 630N 
through all degrees of knee joint flexion/extension.64 Its ultimate tensile strength of was 
found to be 1730 N, with a linear stiffness of 182 N/mm and 12.8 N-m for energy 
absorbed at failure, although such properties have been found to increase during 
development and diminish with age.65-67 The maximum strain that a ligament can endure 
before failure is between 12 and 15%.68 When exposed to strain, the ACL demonstrates 
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triphasic behavior, starting with a non-linear, toe region where the ligament exhibits low 
amount of stress per unit strain.4 This results from a lateral contraction of fibrils, the 
release of water, and straightening of the crimp pattern. Once the crimp pattern has fully 
straightened, force is directly applied to the collagen triple helix and interfibrillar 
slippage occurs between crosslinks, forming a linear region in which stress increases per 
unit strain.69-71 Eventually, collagen fibers begin to defibrillate, leading to a slight 
decrease in stress per unit strain and failure.4, 69, 72 A biomaterial scaffold that can 
replicate this mechanical behavior and integrate with the native tissue is necessary for 
the development of a successful tissue engineered ligament. 
1.4  Current Biomaterial Scaffolds for Ligament Tissue Engineering 
1.4.1    Natural Polymers 
Biocompatible and degradable biomaterials that have been investigated for 
ligament tissue engineering include natural polymers, such as collagen and silk, and 
synthetic materials. Type I collagen was selected for tissue engineering because, in 
addition to its abundance in ligament tissue, it is able to support the growth of fibrous 
tissue. Examples of tissue-engineered approaches using collagen fibers are presented 
extensively throughout the literature.73, 74 Dunn et al. constructed fibroblast-seeded 
scaffolds composed of type I collagen fibers and found that such devices remain viable 
after implantation, showing excellent biocompatibility, enhanced cell attachment, 
proliferation, and extracellular matrix production.74, 75 Nevertheless, these scaffolds are 
unable to maintain the mechanical integrity necessary to restore ligament function. 
Several strategies have been attempted to enhance the mechanical properties of  
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collagen-derived scaffolds, including cross-linking and copolymerization/blending with 
synthetic polymers.11, 20, 31, 76-81. Despite these efforts, relatively quick in vivo 
degradation and the resulting loss of mechanical strength are still major concerns with 
using collagen fibers for ligament tissue engineering.73, 82 High cost, variability, complex 
handling properties, and potential disease transmission further limit the use of collagen, 
prompting the search for an improved biomaterial.31, 83 
 Due to its high tensile strength and linear stiffness, biocompatibility, and 
biodegradability, silk has received renewed interest as a potential biomaterial for tissue 
engineering.84-88 The excellent mechanical properties of silk result from the high 
homogeneity of its secondary structure (β-sheet), extensive hydrogen bonding, and 
crystallinity. Silk is composed of a fibroin core and a glue-like sericin cover, and 
although sericin in silk has been shown to cause adverse problems with 
biocompatibility, there are several methods to remove it before usage. As a result, 
scaffolds constructed of silk fibroin demonstrate good biocompatibility and have been 
shown to support cell adhesion.89 In addition, by coating the surface of these scaffolds 
with RGD sequences, increased cellular attachment, proliferation, and extracellular 
matrix production have been observed.90 When organized into an appropriate wire-rope 
geometry, silk fibroin exhibits mechanical properties similar to the native ACL.89 For 
example, Altman et al. constructed a tissue-engineered device consisting of a twisted 
fibrous matrix composed of silk fibers arranged into a hierarchical structure similar to 
the native ACL. Through modification of scaffold architecture, the stiffness of the 
scaffold can also be decreased to prevent stress shielding while maintaining tensile 
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strength. Silk undergoes proteolytic degradation at a rate that is dependent on its 
environment, but typically silk fibers lose their tensile strength within one year in vivo 
and degrade completely within two years. The slow rate of silk degradation allows for 
gradual load transfer from the polymer scaffold to newly formed tissue.32 Even though 
silk has demonstrated much promise for ligament tissue engineering, its dependence on 
scaffold architecture to achieve mechanical properties limits independent control of 
mechanical strength and degradation necessary to promote effective load transfer.  
Along with collagen and silk, other natural polymers have been investigated for 
potential use in ACL reconstructions. Funakoshi et al. constructed a tissue engineered 
scaffold from novel, chitosan-based hyaluronan hybrid polymer fibers, which were 
shown to exhibit enhanced mechanical properties and biological effects in vitro.91 
Majima et al. investigated the effect of alginate-based chitosan hybrid polymers on 
fibroblast adhesion, extracellular matrix synthesis, and mechanical properties.92 Finally, 
Messenger et al. investigated the ability of enamel matrix derivative to enhance tissue 
induction around scaffolds used in ACL reconstruction.93 These studies have 
considerable potential for ligament tissue engineering; however, they are still in 
preliminary stages of development and are far removed from clinical applications. 
Overall, despite the aforementioned advantages of natural polymers, concerns with mass 
production, variability, and the lack of independent control of degradation rate and 




1.4.2    Synthetic Polymers 
In addition to natural polymers, biodegradable, synthetic polymers have been 
investigated for ACL repair, including poly (glycolic acid) (PGA), poly (L-lactic acid) 
(PLLA), poly (lactic-co-glycolic acid) (PLGA), polydioxanone (PDS), and poly 
(desamino-tyrosyl-tyrosine ethyl carbonate) (poly (DTE carbonate)).4, 19, 94-101 Similar to 
nondegradable synthetic polymers used to construct permanent prosthesis, there is no 
limit to graft supply and no risk of disease transmission. Unlike natural polymers, such 
as silk, which rely on modification of scaffold architecture to alter mechanical 
properties, the performance properties of synthetic polymers can also be controlled with 
polymer chemistry. For instance, the mechanical properties of a device may be 
controlled by altering the degree of polymer crystallinity or changing its molecular 
weight. 
 PGA and PLLA are excellent candidates for ligament tissue engineering because 
they are biocompatible, do not elicit unfavorable foreign body responses, and naturally 
degrade into non-toxic byproducts (glycolic acid, lactic acid). Additionally, because 
tissue engineered scaffolds are eventually replaced with neotissue, the fatigue properties 
of PGA and PLLA are not a concern. As a result, PGA, PLLA, and PLGA have been 
extensively studied for potential use in ACL reconstruction. 4, 19, 96-101 In particular, 
Laurencin et al. developed a series of cell-seeded, three-dimensional scaffolds from 
PGA, PLLA, and PLGA using a novel braiding technique designed to enhance 
mechanical properties and promote tissue infiltration, with PLLA proving to be the best 
option for ACL repair.102, 103 Similar to native ligament tissue, these braided scaffolds 
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have a hierarchical structure composed of fibers arranged into bundles and wound 
throughout the thickness of the scaffold. This braiding technique was developed to 
create scaffolds with controlled pore size, integrated pores, resistance to wear and 
rupture, and mechanical properties comparable to the ACL. In in vitro studies, ACL 
fibroblasts were found to conform to the geometry of the scaffolds, exhibit spindle-like 
morphologies, and demonstrate extracellular matrix production. Additionally, cellular 
proliferation, tissue growth, and long-term extracellular matrix production were 
enhanced in the presence of fibronectin, an adhesion protein found in the extracellular 
matrix of native ligament tissue. These results suggest that braided scaffolds constructed 
of PLLA may become a viable option for ACL repair.102-104  
Other synthetic polymers explored for potential use in ligament tissue 
engineering include PDS and poly (DTE carbonate). Buma et al. studied autogenous 
reconstruction of the ACL in goats in the presence of a degradable augmentation device 
composed of PDS and found that, after 6 weeks, a rapid decrease in strength was 
observed for augmented transplants.95 In contrast, non-augmented transplants 
demonstrated a gradual increase in strength. These results suggest that PDS is a poor 
choice for ligament tissue engineering due to its rapid degradation. Bourke et al. 
fabricated ACL scaffolds from poly (DTE carbonate) fibers and found that these 
scaffolds have mechanical properties similar to the native ACL, and that they keep a 
much higher ultimate tensile strength (87% of original) after 30 weeks of degradation 
than PLLA (7% of original).94 Despite these advantages, the parallel arrangement of 
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poly (DTE carbonate) fibers in these scaffolds leaves them susceptible to long-term 
failure due to fatigue and creep. 
Overall, current research has shown that synthetic, biodegradable polymers can 
be viable options for ACL reconstruction; however, these materials are still limited in 
their ability to serve as ligament replacements. This is because the majority of these 
polymers lack the inherent material properties necessary to restore the mechanical 
strength and elasticity of the ACL. To overcome these mechanical limitations, a number 
of scaffolds derive their properties from their geometry and method of fabrication; 
however, this requires an understanding of how each structure behaves mechanically 
relative to one another. Changes in the mechanics of scaffold architecture due to 
degradation or repeated loading then increase the complexity of the graft, making it 
difficult to optimize scaffold design to promote effective load transfer. In addition to 
scaffold fabrication, polymer chemistry can be tailored to modulate these performance 
properties; however, a number of these structure-property relationships have overlapping 
components that complicate material design. For example, it is widely accepted that 
polymer crystallinity can be used to predict polymer modulus, yet highly crystalline 
polymers have also been shown to demonstrate slower hydrolytic degradation than 
amorphous polymers.105 Without mechanisms to isolate specific structure-property 
relationships, these polymers are unable to balance the dual impact of tensile properties 
and the rate of degradation on the regeneration of ligament tissue. Additionally, the 
degradation mechanism for the majority of these polymers is non-specific hydrolysis, 
which makes it difficult to tailor scaffold degradation to complement neotissue 
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formation. Because current synthetic polymers are unable to either match the mechanical 
behavior of the ACL or integrate with native tissue remodeling, an improved material is 
needed to develop a successful tissue engineered ligament. 
1.5  Segmented Polyurethane Elastomers 
 Due to the aforementioned limitations of current synthetic polymers, 
polyurethane elastomers have received growing interest for ligament tissue 
engineering.106-109 Polyurethanes were first developed by Otto Bayer of I. G. 
Farbenindustrie, Leverkusen, Germany, in 1937.106 Since then, polyurethanes have been 
used in a wide range of industrial applications, including machinery, textiles, packaging, 
adhesives, and sealants.110, 111 Because of their outstanding mechanical properties and 
established biocompatibility, polyurethanes have also been used in a variety of 
biomedical applications over the past 40 years.106, 112-114 Polyurethane chemistry dictates 
the physical, biological, and mechanical properties of these polymers and can be tailored 
to provide a variety of materials, such as soft elastomers, rigid thermosets, and foams.106, 
110, 111, 115
 Therefore, understanding the hierarchical structure of polyurethanes and 
related materials, along with relevant structure-property relationships, is essential for 
effective biomaterial design. 
 Polyurethanes are a class of polymers that consist of urethane (-NH-CO-O-) 
linkages, typically generated by the reaction of isocyanates with hydroxyl-functional 
molecules by addition to the carbon-nitrogen bond.115-117 Similarly, polyureas contain 
urea linkages (-NH-CO-NH-) and are generated by the addition of isocyanates and 
primary amine groups. Polyurethane and polyurea elastomers used for biomedical 
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applications are typically linear alternating block copolymers that consist of relatively 
high molecular weight soft segments linked with urethane/urea containing hard 
segments.106-108 Common soft segments include hydroxyl-terminated polyethers, 
polyesters, and polycarbonates, all of which have relatively low glass transition 
temperatures. In contrast, hard segments usually have high glass transition temperatures 
and are characterized by semicrystalline, aromatic or aliphatic diisocyanates linked with 
a low molecular weight chain extender.106 Thermodynamic incompatibility between 
these segments drives microphase separation in which hard segments form glassy, 
semicrystalline domains that, in polymers of lower hard segment content, are dispersed 
within an amorphous, rubbery matrix.106-108, 118, 119 These hard domains are stabilized by 
hydrogen bonds between urea and urethane groups and serve as physical crosslinks and 
structural reinforcement for the soft segment matrix.106, 118, 119 It is this           
microphase-separated morphology that dictates the ease of processing of polyurethane 
elastomers. This is because, unlike traditional elastomers, which derive their elasticity 
from an amorphous network interconnected with chemical crosslinks, the physical 
crosslinks of polyurethane elastomers are thermo-reversible and so breakup upon 
heating or dissolution. 
Along with this ease of processing, the mechanical properties of segmented 
block copolymers are strongly dependent on this microphase-separated morphology.  
Deformation of segmented block copolymers begins with elastomeric stretching of the 
soft segment matrix, as indicated by a low initial modulus in the stress-strain curve, 
Figure 1.2.120 Hard domains then breakup at flaws and begin to rotate into the strain 
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direction, causing a plateau of almost constant stress. This eventually results in the 
formation of microfibrils consisting of small, semi-crystalline hard domains separated 
by strain-crystallized soft segment chains that undergo strain hardening at higher 
strains.120 Ultimately, these hard domains shear yield at a critical strain and the material 
fails.120. Because of this deformation profile, polyurethanes and polyureas have excellent 
mechanical properties, including high tensile strength, elongation to failure, fatigue life, 
and wear resistance, without additional processing. In addition to mechanical behavior, 
microphase separation has also been shown to directly influence the rate and extent of 
biodegradation.121, 122 Factors that influence the degree of phase separation include soft 
segment molecular weight, hard and soft segment chemistries, and the hard to soft 
segment ratio.123-127 Therefore, these variables can be adjusted to modulate the 
performance properties of polyurethanes and polyureas. For example, increased hard 
segment content puts greater constraint on the soft segment matrix, which leads to a 
higher initial modulus and strain hardening at a lower strain.120, 128 
 
 
Figure 1.2. Effect of mechanical stretch on polyurethane deformation.120 
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Overall, the correlation between polyurethane chemistry and microphase 
separation, and thus performance properties, provides a means to elucidate key 
structure-property relationships. As with homogenous, biodegradable polymers, a 
number of these relationships have overlapping components that complicate material 
design for tissue engineering applications. A key challenge then is to isolate      
structure-property relationships that are essential to the development of engineered 
tissue. A polymer system with several mechanisms to modulate physical properties 
would provide the tools necessary to observe such phenomena. Due to the exceptional 
tunability of polyurethanes and polyureas, segmental modification of these polymers can 
be used to generate a library of polymers with broad structural diversity and a myriad of 
performance properties to better probe specific tissue-biomaterial interactions. Greater 
understanding of such structure-property relationships would then allow for rational 
design of a tissue engineered scaffold that promotes effective load transfer. 
1.6  Polyurethanes in Biomedical Applications 
As stated previously, in addition to the aforementioned mechanical requirements, 
tissue engineered scaffolds must be biocompatible and biodegradable. Polyurethanes 
used for biomedical applications have traditionally been intended for biostable,        
long-term use, such as cardiovascular applications and as artificial organs.106, 114 
Aromatic diisocyanates were often chosen for these materials due to their enhanced 
mechanical properties; however, concerns that the degradation of these diisocyanates 
(i.e., 4, 4’-methylenediphenyl diisocyanate (MDI), 2, 4-toluene diisocyanate (TDI)) can 
generate potentially carcinogenic byproducts (i.e., 4, 4’-methylenedianiline (MDA), 2, 
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4-toluene diamine (TDA)) have limited their transition to biodegradable polymers.109, 129-
131
 As a result, aliphatic diisocyanates, such as hexamethylene diisocyanate (HDI) and 
L-lysine diisocyanate (LDI), have received interest for tissue engineering.126, 132-143 
Unlike aromatic diisocyanates, polyurethanes prepared from aliphatic diisocyanates 
have been reported to degrade to non-cytotoxic compounds in vitro and in vivo.144, 145 
LDI and HDI-based biodegradable polyurethanes have also demonstrated excellent 
mechanical properties and good biocompatibility, as well as promoted cell-material 
interactions necessary for tissue formation.146-148 In addition to biocompatible 
diisocyanates, biodegradable hard segments composed of enzyme-labile chain extenders 
have been used to synthesize polyurethanes for tissue engineering.136, 145, 149 Degradation 
of these linkages is dependent on hard segment crystallinity; however, crystallinity is a 
well-established barrier to degradation. Additionally, enhanced hard segment 
crystallinity leads to an increase in supramolecular interactions (i.e., hydrogen bonding) 
that dictate the mechanical properties of polyurethane elastomers. Due to the interactions 
among crystallinity, degradation rate, and mechanical strength, biodegradable hard 
segments limit the inherent tunability of polyurethane elastomers by inhibiting 
independent control of these structure-property relationships.  
In contrast, the use of biodegradable soft segments can potentially decouple the 
effects on polyurethane structure on degradation rate and mechanical properties. 
Polyurethanes have been synthesized from a number of biodegradable soft segments, 
including poly (lactic acid), poly (glycolic acid), and poly (ε-caprolactone) (PCL).133-137, 
143, 150-156
 These polyols were selected based on their established hydrolytic degradation 
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in vitro and in vivo. As a result, polyurethane degradation is dependent on soft segment 
content, chemistry, and molecular weight. Several polyurethanes composed of these 
polyols have demonstrated biocompatibility and excellent mechanical properties, as well 
as promoted tissue remodeling.145, 153 Indeed, Gisselfalt et al. developed a series of  
PCL-based poly(urethane urea) fibers for ligament tissue engineering that displayed high 
tensile strength, modulus, and fatigue resistance, as well as supported ingrowth of 
connective tissue.128, 157 Nonetheless, as with biodegradable polyesters previously used 
for ligament tissue engineering, degradation of these soft segments is dictated by      
non-specific hydrolysis, which makes it difficult to tailor polyurethane degradation to 
complement tissue regeneration.  
Furthermore, the semi-crystalline nature of some of these soft segments can 
contribute to the performance properties of these materials. For example, PCL of higher 
molecular weight can lead to increased crystallinity of the soft segment, and thus a 
corollary increase in the modulus and tensile strength, along with a decreased rate of 
degradation.126, 136 Therefore, soft segment crystallinity further compounds the 
complexity of polyurethane morphology and derived properties, which makes 
independent control of polyurethane structure-property relationships through segmental 
modifications difficult. In order to disrupt the crystallinity of PCL and achieve a greater 
range of degradation profiles, PCL and poly (ethylene glycol) (PEG) copolymers have 
been investigated; however, the hydrophilicity of PEG increases water uptake of the 
resulting polyurethane, which increases the rate of hydrolytic degradation.144, 150, 153, 158-
160
 Overall, although segmented block copolymers possess the tools necessary to tailor 
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biomaterial chemistry and thus provide independent control of degradation and 
mechanical properties, non-specific degradation of current polyurethane elastomers 
makes it difficult to complement scaffold degradation with ligament regeneration. 
1.7  System-Responsive Degradation 
In general, the design of biomaterial scaffolds for tissue engineering is currently 
limited by the lack of independent control over mechanical properties and degradation 
and the difficulty of matching non-specific degradation with neotissue formation. This is 
because, without appropriate mechanical cues, neotissue cannot successfully regenerate 
the hierarchical structure of ACL tissue. Current research has established that 
mechanical stimulation increases fibroblast proliferation, and that this effect is 
dependent on the type, magnitude and duration of loading.19, 161-164 In addition, cyclic 
stretch causes cells to adopt an elongated, spindle-like morphology consistent with the 
ligament phenotype.161, 165-168 Mechanical loading is also needed to induce cellular 
alignment via restructuring of the actin cytoskeleton.165, 169, 170 The orientation of 
fibroblasts with respect to mechanical loading is of particular interest because of its 
influence on de novo tissue formation.166, 171-174 Fibroblasts oriented parallel to the 
direction of stretch demonstrate greater protein synthesis than cells aligned 
perpendicular to the direction of stretch, as well as generate an oriented collagen 
matrix.166, 171 These effects have clear relevance to the mechanical properties of the 
resulting tissue. Finally, physical loading has been shown to increase protein synthesis, 
specifically type I collagen, which is of particular importance in the ACL due its role in 
establishing tensile properties.161, 165-167, 170, 175-177 Overall, these studies establish the 
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need for mechanical stimulation to develop highly organized, cable-like tissue, 
indicative of the native ACL.  
Because of this dependency on mechanical loading, a key challenge in the design 
of a successful tissue engineered ligament is to facilitate load transfer from the 
biodegradable scaffold to newly formed tissue. Initially, the biodegradable scaffold 
should exhibit sufficient mechanical properties to provide immediate restoration of 
ligament function. Isolated cells should then generate neotissue at a rate complementary 
to scaffold degradation so that the mechanical integrity of the ligament is sustained 
throughout the remodeling process up until the injured tissue is completely replaced.4, 11, 
178
 Because the level of load borne unto de novo tissue dictates remodeling and thus, 
collagen alignment, a degradation rate that does not match new tissue formation can lead 
to either graft rupture (too fast) or stress shielding (too slow).4, 19, 89 With stress 
shielding, the lack of collagen alignment can shift the dynamics of ligament remodeling 
toward degradation, which reduces the load-bearing capacity of the newly formed tissue. 
In order to integrate with native ligament remodeling and maintain mechanical 
functionality, new structure-property models are needed to elucidate the mechanisms of 
load transfer. A polymeric system with control over degradation rate and mechanical 
properties would provide insight into these mechanisms and allow for rational design of 
tissue engineered constructs. Biodegradable polyurethanes can be tailored to isolate the 
effects of polymer structure on specific performance properties; however, non-specific 
degradation remains problematic.  
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System-responsive degradation would eliminate this limitation by integrating 
polyurethane biodegradation with native ligament remodeling. As stated previously, 
during tissue regeneration, fibroblasts produce enzymes that systematically break down 
and remove the existing extra cellular matrix.179 In particular, matrix metalloproteinase 
(MMP) production, including MMP-1 and MMP-2, is upregulated in response to 
ligament rupture and mechanical stimulation, with MMP-2 serving as the most efficient 
enzyme associated with type I collagen degradation.180-182 The specificity of these 
enzymes has been extensively investigated with cleavage localized to the (Gly775-Ile776) 
site of the triple-helical collagen.183-185 By incorporating this collagen oligopeptide 
sequence into the design of a novel biomaterial, guided scaffold degradation can be 
achieved. Moreover, integration of this enzyme-labile peptide sequence into the soft 
segment of a polyurethane elastomer would provide a means to decouple specific effects 
of polyurethane structure on performance properties.  
For this study, an enzyme-labile peptide sequence with established specificity to 
MMP-2 was conjugated to ether-based polyols to form collagen-mimetic soft segments, 
Figure 1.3. Synthetic routes were first developed to generate reactive end groups 
necessary for peptide coupling. Upon successful conjugation, biodegradable soft 
segments were then incorporated into the structure of linear polyurea elastomers. By 
varying soft segment chemistry, soft segment molecular weight, and the hard to soft 
segment ratio, a series of cell-responsive, biodegradable polyureas was developed to 
elucidate key structure-property relationships necessary to complement neotissue 
formation. Overall, a novel biomaterial that combines the strength and tunability of 
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synthetic elastomers with cell-responsive degradation will assist in the development of 
















END GROUP FUNCTIONALIZATION OF ETHER-BASED POLYOLS 
 
2.1  Introduction 
In this study, ether-based soft segments were functionalized to enable facile 
coupling to collagen-derived peptide sequences. By varying soft segment chemistry 
(PEG; poly (tetramethylene ether glycol) (PTMG)) and molecular weight (PEG: 1000, 
2000 g/mol; PTMG: 1000 g/mol), a series of biodegradable soft segments that feature 
cell-responsive degradation can be developed. This library of soft segments will be used 
to elucidate the effects of polyol chemistry and molecular weight on the performance 
properties of polyureas. To this end, synthetic strategies were first developed to 
functionalize polyols with carboxylic acid end groups required to covalently bond with 
peptide sequences. Such end groups were then activated with N-hydroxysuccinimide 
(NHS) ester derivatives to serve as more favorable leaving groups for peptide coupling. 
In addition, carboxylic acid derivatives of higher molecular weight polyethers (PEG: 
6000, 10000 g/mol; PTMG: 2900 g/mol) were functionalized with terminal amine 




Figure 2.1. Synthetic approach to create peptide-based soft segments. 
 
2.2  Carboxylic Acid Functionalization 
 In their native state, polyethers, such as PEG and PTMG, contain hydroxyl 
groups that often require activation or modification before conjugation to other 
molecules can occur. Functionalization of these polyols can be achieved through 
acylation with an anhydride to yield stable ester derivatives terminating in free 
carboxylate groups.186 For example, modification of PEG with succinic anhydride in the 
presence of 4-(Dimethylamino) pyridine (DMAp) and triethylamine (Et3N) yields      
bis-modified products equipped with carboxylates at either end.187-191 Succinic 
anhydride has a five-atom cyclic structure that is highly reactive toward nucleophiles, 
including hydroxyl and amine groups. Nucleophilic attack at one of the carbonyl groups 
opens the anhydride ring, forming a covalent bond with that carbonyl and releasing the 
other to create a free carboxylic acid group.192 The currently accepted mechanism for 
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such acylation involves the pre-equilibrium formation of an acylpyridinium cation 
generated from the reaction of succinic anhydride and DMAp.193 DMAp is a commonly 
used catalyst used to accelerate the acylation of alcohols and amines. Hydroxyl groups 
react with the acylated catalyst in the rate-determining second step to form an ester 
linkage, along with the deactivated catalyst. The auxiliary base Et3N is then utilized to 
recover the deactivated catalyst. In the current study, PEG and PTMG soft segments of 
varying molecular weight were reacted with an excess of succinic anhydride in the 
presence of DMAp and Et3N to generate carboxylic acid derivatives. 
2.2.1   Materials 
 Poly (ethylene glycol) (PEG; Mn ~1000, 2000, 6000, 10000 g/mol) was obtained 
from Fluka Chemical. Poly (tetramethylene ether glycol) (PTMG; Mn ~1000, 2900 
g/mol) was obtained from Polysciences, Inc. Succinic anhydride, 4-(Dimethylamino) 
pyridine (DMAp), triethylamine (Et3N), 1,4-dioxane, dimethylformamide (DMF), 
diethyl ether, and deuterated chloroform (CDCl3) were obtained from Sigma Aldrich and 
used as received. Dichloromethane (DCM) was also obtained from Sigma-Aldrich but 
dried over 4Å molecular sieves. 
2.2.2   Methods 
PEG and PTMG diacids were prepared by esterification of each polyol with 
excess succinic anhydride in the presence of DMAp and Et3N, Figure 2.2. Succinic 
anhydride, DMAp, and Et3N were dissolved in 1, 4-dioxane and then added to a solution 
of PEG or PTMG in 1, 4-dioxane
. 
The mixture was then stirred for 12 hours at 90°C 
under nitrogen. After cooling to room temperature, 1, 4-dioxane was removed by rotary 
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evaporation, and the condensed solution was filtered to remove excess succinic acid. 
PEG derivatives were re-dissolved with DMF and precipitated for ten minutes from 
excess diethyl ether (10:1) that had cooled in a salt ice bath. Following vacuum 
filtration, the final polymer was dried under vacuum at room temperature overnight. 
PTMG derivatives were re-dissolved with DCM and washed twice with distilled water 
(1:1). DCM was then removed by rotary evaporation and vacuum-dried to remove 
residual solvent. Fourier transform infrared (FTIR) spectroscopic analysis was 
performed on a Bruker TENSOR 27 spectrometer to confirm end group 
functionalization. Percent functionalization was quantified with proton nuclear magnetic 





Figure 2.2. Synthesis of carboxylic acid functionalized PEG. 
 
2.2.3   Results 
Synthesis of PEG (1000) diacid  
PEG (1000) (10.00 g, 0.01 mol), succinic anhydride (4.00 g, 0.04 mol), DMAp 
(2.44 g, 0.02 mol), and Et3N (3.06 mL, 0.022 mol) were reacted as previously described. 
In this way, PEG (1000) diacid was obtained as a white, waxy solid (9.12 g, 76% yield). 
Carboxylic acid functionalization and ester formation (1732 cm-1, C=O) were confirmed 
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with FTIR spectroscopy, Figure 2.3. Percent functionalization was calculated to be 
~93% using NMR spectroscopy. 1H-NMR (δ, ppm): 2.64 (m, 8H, -CH2COO-), 3.64 (m, 
85H, -CH2O-), 4.25 (t, 4H, -CH2OCO-). 
 
 
Figure 2.3. FTIR spectra of PEG (1000) carboxylic acid functionalization. 
 
Synthesis of PEG (2000) diacid 
PEG (2000) (10.00 g, 0.005 mol), succinic anhydride (2.00 g, 0.02 mol), DMAp 
(1.22 g, 0.01 mol), and Et3N (1.53 mL, 0.011 mol) were reacted as previously described. 
In this way, PEG (2000) diacid was obtained as a white, waxy solid (9.57 g, 87% yield). 
Carboxylic acid functionalization and ester formation (1732 cm-1, C=O) were confirmed 
with FTIR spectroscopy, Figure 2.4. Percent functionalization was calculated to be 
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~91% using NMR spectroscopy. 1H-NMR (δ, ppm): 2.64 (m, 8H, -CH2COO-), 3.64 (m, 
176H, -CH2O-), 4.25 (t, 4H, - CH2OCO-). 
Synthesis of PEG (6000) diacid 
PEG (6000) (10.00 g, 1.67 mmol), succinic anhydride (0.67 g, 6.67 mmol), 
DMAp (0.41 g, 3.33 mmol), and Et3N (0.51 mL, 3.67 mmol) were reacted as previously 
described. In this way, PEG (6000) diacid was obtained as a white, brittle solid (8.13 g, 
79% yield). Carboxylic acid functionalization and ester formation (1730 cm-1, C=O) 
were confirmed with FTIR spectroscopy, Figure 2.4. Percent functionalization was 
calculated to be ~93% using NMR spectroscopy. 1H-NMR (δ, ppm): 2.64 (m, 8H,           
-CH2COO-), 3.64 (m, 540H, -CH2O-), 4.25 (t, 4H, - CH2OCO-). 
 
 
Figure 2.4. FTIR spectral comparison of PEG diacid syntheses. 
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Synthesis of PEG (10000) diacid  
PEG (10000) (10.00 g, 0.001 mol), succinic anhydride (0.60 g, 0.006 mol), 
DMAp (0.49 g, 0.004 mol), and Et3N (0.613 mL, 0.0044 mol) were reacted as 
previously described. In this way, PEG (10000) diacid was obtained as a white, brittle 
solid (8.13 g, 80% yield). Carboxylic acid functionalization and ester formation (1726 
cm-1, C=O) were confirmed with FTIR spectroscopy, Figure 2.4. Percent 
functionalization was calculated to be ~91% using NMR spectroscopy. 1H-NMR (δ, 
ppm): 2.64 (m, 8H, -CH2COO-), 3.64 (m, 904H, -CH2O-), 4.25 (t, 4H, -CH2OCO-). 
Synthesis of PTMG (1000) diacid  
PTMG (1000) (7.14 g, 7.14 mmol), succinic anhydride (2.86 g, 28.56 mmol), 
DMAp (1.75 g, 14.28 mmol), and Et3N (2.19 mL, 15.71 mmol) were reacted as 
previously described. In this way, PTMG (1000) diacid was obtained as a clear, viscous 
liquid (7.20 g, 84% yield). Carboxylic acid functionalization and ester formation (1736 
cm-1, C=O) were confirmed with FTIR spectroscopy, Figure 2.5. Percent 
functionalization was calculated to be ~92% using NMR spectroscopy. 1H-NMR (δ, 
ppm): 1.62 (m, 55H, -CH2-), 2.63 (m, 8H, -CH2COO-), 3.41 (m, 51H, -CH2O-), 4.12 (t, 
4H, - CH2OCO-). 
Synthesis of PTMG (2900) diacid  
PTMG (2900) (10.00 g, 3.45 mmol), succinic anhydride (1.38 g, 13.79 mmol), 
DMAp (0.84 g, 6.90 mmol), and Et3N (1.06 mL, 7.59 mmol) were reacted as previously 
described. In this way, PTMG (2900) diacid was obtained as a clear, viscous liquid (9.19 
g, 86% yield). Carboxylic acid functionalization and ester formation (1736 cm-1, C=O) 
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were confirmed with FTIR spectroscopy, Figure 2.5. Percent functionalization was 
calculated to be ~95% using NMR spectroscopy. 1H-NMR (δ, ppm): 1.62 (m, 160H,       
-CH2-), 2.63 (m, 8H, -CH2COO-), 3.41 (m, 156H, -CH2O-), 4.12 (t, 4H, - CH2OCO-). 
 
 
Figure 2.5. FTIR spectral comparison of PTMG diacid syntheses. 
 
2.3  NHS Activation of Carboxylic Acid Derivatives 
Once successful functionalization has been verified, carboxylic acid derivatives 
of PEG and PTMG can be used to react with other molecules via nucleophilic acyl 
substitution; however, due to the relatively poor reactivity of carboxylic acid end groups, 
activation with a superior leaving group is often necessary to ensure optimal 
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conjugation. The use of NHS ester derivatives is one of the more common strategies to 
activate such acylating agents.194-200 An NHS ester is often formed by the reaction of a 
carboxylate with NHS in the presence of a carbodiimide, such as 
dicyclohexylcarbodiimide (DCC), in a non-aqueous medium.191, 197, 201-203 Carbodiimides 
are cross-linking agents used to mediate the formation of amide or ester linkages 
between a carboxylate and an amine or hydroxyl group, respectively.204 N-substituted 
carbodiimides react with carboxylic acids to form highly reactive, O-acylisourea 
derivatives, which then react with a nucleophile to form a bond, generating an isourea 
byproduct.205 In the present study, the O-acylisourea intermediate reacts with the 
hydroxyl group of free NHS, forming an ester linkage and essentially upgrading to a 
better leaving group. A potential limitation to DCC coupling reactions is the 
spontaneous rearrangement of the O-acylisourea to an inactive N-acylisourea, which is 
enhanced in aprotic solvents such as DMF.186 To minimize this effect on NHS activation 
of carboxylate groups, a large excess of DCC and NHS is typically used.191, 197 In the 
current study, carboxylic acid functionalized polyethers from the previous step were 
reacted with excess NHS and DCC to form NHS ester derivatives.  
2.3.1   Materials 
 PEG and PTMG diacids were prepared as previously described. 
Dicyclohexylcarbodiimide (DCC) was purchased from Fluka Chemical. Ethyl acetate 
was obtained from Fisher Scientific. N-hydroxysuccinimide (NHS), hexane, diethyl 
ether, and deuterated chloroform (CDCl3) were obtained from Sigma Aldrich and used 
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as received. Dichloromethane (DCM) was obtained from Sigma-Aldrich and dried over 
4Å molecular sieves. 
2.3.2   Methods 
 Activated NHS ester derivatives of PEG and PTMG diacids were prepared in the 
presence of excess NHS and DCC, Figure 2.6. PEG or PTMG diacid and NHS were 
first dissolved in DCM, and then excess DCC was added. After stirring for 12 hours at 
room temperature, precipitated dicyclohexylurea was removed with vacuum filtration. 
For PEG diacid derivatives, the filtered solution was condensed by rotary evaporation 
and re-dissolved in ethyl acetate. Additional urea byproduct was removed and the 
filtered solution was then precipitated for 10 minutes from excess diethyl ether (10:1) 
that had cooled in a salt ice bath. PEG derivatives of higher molecular weight (2000, 
6000, and 10000 g/mol) were retrieved using vacuum filtration and dried under vacuum 
at room temperature overnight. Because NHS-activated PEG (1000) diacid was a 
viscous liquid, diethyl ether was decanted and the polymer residue was re-dissolved with 
DCM. DCM was then removed by rotary evaporation and the polymer residue was dried 
under high vacuum to remove residual solvent. After filtration, PTMG diacid derivatives 
were washed once with distilled water (1:1) and then precipitated from excess hexane 
(10:1) that had been cooled in a salt ice bath. After ten minutes, hexane was decanted, 
and the polymer residue was re-dissolved with DCM. DCM was removed by rotary 
evaporation and the polymer residue was vacuum-dried to remove residual DCM. 
Infrared spectroscopic analysis was performed on a Bruker TENSOR 27 spectrometer to 
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confirm end group functionalization. Percent functionalization was quantified with     
1H-NMR spectroscopy using a Mercury 300 MHz spectrometer. 
 
 
Figure 2.6. NHS activation of PEG diacid in the presence of DCC. 
 
2.3.3   Results 
NHS activation of PEG (1000) diacid  
PEG (1000) diacid (3.09 g, 2.575 mmol), NHS (2.96 g, 25.75 mmol), and DCC 
(6.91 g, 33.47 mmol) were reacted as previously described. In this way, NHS- PEG 
(1000)-NHS was obtained as a yellow, viscous liquid (2.53 g, 70% yield). Formation of 
activated NHS ester derivatives (1738, 1778, 1811 cm-1, C=O) was confirmed with 
FTIR spectroscopy, Figure 2.7. 1H-NMR (δ, ppm): 2.71 (s, free NHS), 2.78 (t, 4H,         
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-CH2COO-), 2.84 (m, 8H, NHS ester), 2.96 (t, 4H, -CH2COON-), 3.64 (m, 85H,             
-CH2O-), 4.27 (t, 4H, -CH2OCO-). 
 
 
Figure 2.7. FTIR spectra of NHS activation of PEG (1000) diacid. 
 
NHS activation of PEG (2000) diacid 
PEG (2000) diacid (3.04 g, 1.38 mmol), NHS (1.59 g, 13.8 mmol), and DCC 
(3.71 g, 17.96 mmol) were reacted as previously described. In this way, NHS-PEG 
(2000)-NHS was obtained as a white, waxy solid (2.92 g, 88% yield). Formation of 
activated NHS ester derivatives (1738, 1778, 1811 cm-1, C=O) was confirmed with 
FTIR spectroscopy, Figure 2.8. 1H-NMR (δ, ppm): 2.71 (s, free NHS), 2.78 (t, 4H,         
-CH2COO-), 2.84 (m, 8H, NHS ester), 2.96 (t, 4H, -CH2COON-), 3.64 (m, 176H,           
-CH2O-), 4.27 (t, 4H, -CH2OCO-). 
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NHS activation of PEG (6000) diacid 
PEG (6000) diacid (8.00 g, 1.29 mmol), NHS (1.49 g, 12.9 mmol), and DCC 
(3.46 g, 16.77 mmol) were reacted as previously described. In this way, NHS-PEG 
(6000)-NHS was obtained as a white powder (6.43 g, 78% yield). Formation of activated 
NHS ester derivatives (1738, 1776, 1807 cm-1, C=O) was confirmed with FTIR 
spectroscopy, Figure 2.8. 1H-NMR (δ, ppm): 2.71 (s, free NHS), 2.78 (t, 4H,                  
-CH2COO-), 2.84 (m, 8H, NHS ester), 2.96 (t, 4H, -CH2COON-), 3.64 (m, 540H,           
-CH2O-), 4.27 (t, 4H, -CH2OCO-). 
 
 
Figure 2.8. FTIR spectral comparison of NHS ester derivatives of PEG diacids. 
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NHS activation of PEG (10000) diacid  
PEG (10000) diacid (3.06 g, 0.299 mmol), NHS (0.35 g, 2.999 mmol), and DCC 
(0.81 g, 3.899 mmol) were reacted as previously described. In this way, NHS-PEG 
(10000)-NHS was obtained as a white, brittle solid (2.80 g, 90% yield). Formation of 
activated NHS ester derivatives (1738, 1774, 1800 cm-1, C=O) was confirmed with 
FTIR spectroscopy, Figure 2.8. 1H-NMR (δ, ppm): 2.71 (s, free NHS), 2.78 (t, 4H,         
-CH2COO-), 2.84 (m, 8H, NHS ester), 2.96 (t, 4H, -CH2COON-), 3.64 (m, 904H,           
-CH2O-), 4.27 (t, 4H, -CH2OCO-). 
 
 
Figure 2.9. FTIR spectral comparison of NHS ester derivatives of PTMG diacids. 
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NHS activation of PTMG (1000) diacid  
PTMG (1000) diacid (3.22 g, 2.68 mmol), NHS (3.09 g, 26.83 mmol), and DCC 
(7.19 g, 34.88 mmol) were reacted as previously described. In this way, NHS-PTMG 
(1000)-NHS was obtained as a yellow, waxy solid (2.90 g, 78% yield). Formation of 
activated NHS ester derivatives (1739, 1782, 1811 cm-1, C=O) was confirmed with 
FTIR spectroscopy, Figure 2.9. 1H-NMR (δ, ppm): 1.62 (m, 55H, -CH2-), 2.74 (t, 4H,    
-CH2COO-), 2.84 (m, 8H, NHS ester), 2.95 (t, 4H, -CH2COON-), 3.41 (m, 51H,             
-CH2O-), 4.14 (t, 4H, -CH2OCO-). 
NHS activation of PTMG (2900) diacid  
PTMG (2900) diacid (7.99 g, 2.57 mmol), NHS (2.97 g, 25.8 mmol), and DCC 
(6.91 g, 33.5 mmol) were reacted as previously described. In this way, NHS-PTMG 
(1000)-NHS was obtained as a white, waxy solid (7.72 g, 91% yield). Formation of 
activated NHS ester derivatives (1743, 1780, 1811 cm-1, C=O) was confirmed with 
FTIR spectroscopy, Figure 2.9. 1H-NMR (δ, ppm): 1.62 (m, 160H, -CH2-), 2.74 (t, 4H,     
-CH2COO-), 2.84 (m, 8H, NHS ester), 2.95 (t, 4H, -CH2COON-), 3.41 (m, 156H,           
-CH2O-), 4.14 (t, 4H, -CH2OCO-). 
2.4  Amine Functionalization 
 Activation of acylated PEG and PTMG compounds with NHS ester groups 
produces a highly reactive polymer that can be covalently modified with various 
molecules to alter end group functionality.186 NHS ester-containing reagents react with 
nucleophiles with release of the NHS leaving group to form an acylated product. For 
example, active NHS ester derivatives can react with short compounds that contain 
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primary amine groups on either end to form an amide bond, which blocks the 
carboxylate group and generates terminal amino groups.206-208 Ethylene diamine (EDA) 
is a popular choice for amine functionalization because its short chain length ensures 
minimal steric effects and virtually no hydrophobic interactions.209, 210 An excess of 
diamine is typically used to ensure both ends of the target molecule react with free 
amine-terminated compounds instead of cross-linking.209 Modification of carboxylate 
groups with diamines can be done in organic solvents, provided the target molecule is 
soluble and stable in such environments.186, 208, 210, 211 For such reactions, an organic base 
is typically added, such as Et3N or DMAp.186 In the current study, NHS-activated,   
PEG-based diacids of higher molecular weight (6000, 10000 g/mol) were end capped 
with excess EDA in the presence of DMAp and Et3N to form amine-terminated soft 
segments for polyurea syntheses. To generate a PTMG-based soft segment of 
comparable molecular weight to PEG, a carboxylic acid derivative of low molecular 
weight was first terminated with amine groups and then subsequently used to end cap a 
higher molecular weight molecule. 
2.4.1   Materials 
 NHS-activated PEG and PTMG diacids were prepared as previously described.  
Ethylene diamine (EDA), 4-(Dimethylamino) pyridine (DMAp), triethylamine (Et3N), 
dimethylformamide (DMF), diethyl ether, and deuterated chloroform (CDCl3) were 
obtained from Sigma-Aldrich and used as received. Dichloromethane (DCM) was 
obtained from Sigma-Aldrich and dried over 4Å molecular sieves. The Kaiser test kit 
was obtained from Fluka Chemical. 
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2.4.2   Methods 
PEG and PTMG diamines were prepared by nucleophilic substitution of      
NHS-activated diacids with excess EDA in the presence of DMAp and Et3N, Figure 
2.10. NHS-activated PEG and PTMG diacids were dissolved in DMF and then added 
drop wise to a solution of EDA, DMAp, and Et3N while stirring. After addition, the 
mixture was stirred at room temperature overnight under nitrogen. Free NHS byproducts 
were removed with vacuum filtration and PEG-based solutions were precipitated for ten 
minutes from excess diethyl ether (10:1) that had been cooled in a salt ice bath. PEG 
diamine was then retrieved with vacuum aspiration and subsequently dried under 
vacuum overnight. After filtration, PTMG solutions were washed with DCM and brine 
(1:1) and then condensed by rotary evaporation. PTMG diamine was finally dried under 
high vacuum to remove residual solvent. Upon successful functionalization, the resulting 
PTMG diamine was used to end cap NHS-activated PTMG 2900 diacid in place of EDA 
to form a PTMG-based control soft segment for polyurea syntheses. Formation of this 
PTMG-based control soft segment followed the same synthetic strategy as EDA-based 
functionalization; however, ultrafiltration was used in place of washing to remove 
excess PTMG 1000 diamine and other contaminants. Infrared spectroscopic analysis 
was performed on a Bruker TENSOR 27 spectrometer to confirm end group 
functionalization. A Kaiser test kit was used to verify the presence of free primary amine 
groups, as indicated by a color shift from yellow to a dark blue/purple hue. Due to 
hydrogen bonding among functional groups, 1H-NMR spectroscopy could not be used to 
quantify end group functionalization. 
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Figure 2.10. Functionalization of NHS-activated PEG diacid with EDA. 
 
2.4.3   Results 
Synthesis of PEG (6000) diamine 
NHS-PEG (6000)-NHS (1.00 g, 0.156 mmol), EDA (62.9 µL, 0.938 mmol), 
DMAp (38.214 mg, 0.313 mmol), and Et3N (47.9 µL, 0.344 mmol) were reacted as 
previously described. In this way, PEG (6000) diamine was obtained as a white, brittle 
solid (0.72 g, 73% yield). Amide formation (1640 cm-1, C=O) was confirmed with FTIR 
spectroscopy, Figure 2.11. In addition, the carbonyl peak at 1730 cm-1 attenuated due to 
the loss of carboxylic acid groups and shifted to 1684 cm-1 because of hydrogen bonding 
among ester linkages. The Ninhydrin assay turned dark blue, indicating free amine 




Figure 2.11. Amine functionalization of PEG (6000) diacid. 
 
Synthesis of PEG (10000) diamine  
NHS-PEG (10000)-NHS (1.00 g, 0.096 mmol), EDA (38.7 µL, 0.577 mmol), 
DMAp (23.51 mg, 0.192 mmol), and Et3N (29.47 µL, 0.212 mmol) were reacted as 
previously described. In this way, PEG (10000) diamine was obtained as a white, brittle 
solid (0.72 g, 54% yield). Amide formation (1629 cm-1, C=O) was confirmed with FTIR 
spectroscopy, Figure 2.12. In addition, the carbonyl peak at 1726 cm-1 attenuated due to 
the loss of carboxylic acid groups and shifted to 1684 cm-1 because of hydrogen bonding 
among ester linkages. The Ninhydrin assay turned dark blue to indicate that free amine 




Figure 2.12. Amine functionalization of PEG (10000) diacid. 
 
Synthesis of PTMG (1000) diamine  
NHS-PTMG (1000)-NHS (0.62 g, 0.448 mmol), EDA (180 µL, 2.69 mmol), 
DMAp (109.4 mg, 0.896 mmol), and Et3N (137.2 µL, 0.985 mmol) were reacted as 
previously described. In this way, PTMG (1000) diamine was obtained as a yellow, 
waxy solid (0.53 g, 92% yield). Amide formation (1658 cm-1, C=O) was confirmed with 
FTIR spectroscopy, Figure 2.13. In addition, the carbonyl peak at 1730 cm-1 attenuated 
due to the loss of carboxylic acid groups. The Ninhydrin assay turned dark blue to 
indicate that free amine groups are present. 
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Synthesis of PTMG-based control soft segment (PTMG (5600) diamine) 
NHS-PTMG (2900)-NHS (0.34 g, 0.103 mmol), PTMG (1000) Diamine (0.53 g, 
0.412 mmol), DMAp (25.2 mg, 0.206 mmol), and Et3N (31.6 µL, 0.227 mmol) were 
reacted as previously described. In this way, PTMG (5600) diamine was obtained as a 
yellow, waxy solid (0.37 g, 64% yield). As expected, carbonyl peaks of ester (1735 cm-1, 
C=O) and amide (1655 cm-1, C=O) linkages were reduced in the FTIR spectra of the 
control soft segment with respect to the internal reference ether peak, Figure 2.14. This 
is because, as the molecular weight of the base polymer increased, the relative ratio of 
all functional groups decreased. The Ninhydrin assay turned dark blue to indicate that 
free amine groups are present. 
 
 
Figure 2.13. Amine functionalization of PTMG (1000) diacid. 
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Figure 2.14. FTIR spectra of PTMG (5600) diamine synthesis. 
 
2.5  Conclusions 
End group functionalization is a useful means to tailor polymer chemistry for 
various applications. In the current study, synthetic routes were developed to modify 
ether-based polyols over a range of molecular weights with carboxylic acid end groups 
necessary for peptide coupling and amine functionalization. Successful functionalization 
of all target polyols was confirmed with FTIR and NMR analysis. As expected, FTIR 
spectra of all carboxylic acid derivatives demonstrated ester formation at 1730 cm-1, 
with relative heights of absorbance with respect to the internal reference ether peak 
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decreasing with increased molecular weight. A similar correlation was observed in the 
FTIR spectra for all NHS-activated compounds. These samples also showed comparable 
increases in the absorbance at 1730 cm-1 due to the generation of NHS esters. 1H-NMR 
analysis verified at least 90% functionalization of all polyols with carboxylic acid end 
groups, with succinate groups demonstrating appropriate chemical shifts upon activation 
with NHS. Amine functionalization of ether-based carboxylic acid derivatives was also 
confirmed with FTIR spectroscopy and a Ninhydrin assay; however, the lack of 
quantitative analysis is a concern as these polymers are used for subsequent syntheses.  
Due to the versatility of these synthetic routes, a broad polymer toolbox was 
generated to enable segmental modification of polyurethane chemistry. Additionally, 
synthesis of highly reactive polyethers provides the means to conjugate such polymers 
with enzyme-labile peptide sequences necessary for system-responsive degradation. In 
the following chapter, functionalized polyols will be utilized to synthesize         
collagen-mimetic soft segments that will then be incorporated into cell-responsive, 
biodegradable polyureas. Because of the structural diversity of these polyols, a library of 
polyureas will be generated to gain a better understanding of intrinsic structure-property 
relationships and their relation to tissue remodeling. This will assist in the development 







SYNTHESIS OF CELL-RESPONSIVE, BIODEGRADABLE POLYUREAS 
 
3.1  Introduction 
Throughout the literature, tissue engineers have modified biomaterial chemistry 
with targeted peptide sequences to modulate cell behavior.194, 197, 212-216 In particular, 
collagenase-sensitive materials, including hydrogels and polyurethane elastomers, have 
been investigated for tissue engineering applications to provide system-responsive 
degradation; however, an enzyme-labile material suitable for ACL repair has yet to be 
developed.145, 196, 217-230 In the previous section, synthetic routes were developed to 
functionalize ether-based polyols with favorable end groups for peptide coupling. This 
chapter will focus on the use of these functionalized, ether-based polyols to synthesize 
peptide-based soft segments, and subsequently, cell-responsive, biodegradable polyureas 
for potential use in ligament tissue engineering.  
NHS-activated carboxylic acid derivatives from the previous step were first 
coupled to collagen-derived peptide sequences to form peptide-polyol-peptide triblocks, 
Figure 3.1.  These triblocks were then end capped with NHS-activated carboxylic acid 
derivatives of the same polyol chemistry to form biodegradable multiblocks. By varying 
the chemistry and molecular weight of these polyols, a library of peptide-based soft 




Figure 3.1. Synthetic design of peptide-based, soft segment multiblocks. 
 




Following amine functionalization, multiblocks were reacted with aliphatic 
diisocyanates (HDI) and diamine chain extenders (EDA) to form linear polyurea 
elastomers, Figure 3.2. Amine-functionalized polyethers of similar molecular weight 
and chemistry as the peptide-polyol multiblocks were also implemented into polyurea 
design to serve as control soft segments. Along with soft segment chemistry and 
molecular weight, the hard to soft segment ratio was varied to produce a library of    
cell-responsive, biodegradable polyureas, Table 3.2. Two ratios of diisocyanate to soft 
segment to chain extender (3:1:2; 5:1:4) were selected to create hard segment weight 
fractions that range from 6-17%. Including polyol controls, the final library of polyureas 
consisted of twelve linear polyurea elastomers. This library should provide the necessary 
comparisons to isolate the effects of hard segment content, polyol chemistry, and soft 
segment molecular weight on performance properties. Understanding these       
structure-property relationships will enable rational design of an improved biomaterial 
scaffold for ligament tissue engineering. 
 
 




Table 3.2. Library of collagen-mimetic polyureas 
 
 
3.2  Synthesis of Enzyme-Labile, Ether-Based Soft Segments 
In order to synthesize cell-responsive, biodegradable polyureas, a      
collagenase-sensitive peptide sequence (GPQGIWGQGK) with specificity to MMP-2 
was coupled to NHS-activated carboxylic acid derivatives of PEG and PTMG to form 
peptide-polyol conjugates. Similar to amine functionalization, NHS ester reagents react 
with α-amines at the N-terminals of protein molecules, as well as ε-amines of lysine (K) 
side chains, to form stable amide bonds.186 Reaction of NHS esters with protein 
molecules occurs at physiological pH, or under slightly basic conditions to accelerate 
coupling with primary amines, and so peptide-polyol conjugation is typically performed 
in buffered solution.191, 196, 197, 199, 219, 226 Even so, the use of buffered media is limited by 
the potential for hydrolysis of NHS esters, which results in a loss of reactivity.  
 In this study, enzyme-labile peptide sequences were used to end cap             
NHS-activated PEG and PTMG diacids to form peptide-polyol-peptide triblocks. The 
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sequence GPQGIWGQG was selected because it is degraded by several MMPs, 
including MMP-2, and it has been reported to be the most rapidly degradable sequence 
among GPQGIXGQG (X = arbitrary amino acid) motifs.219, 231 Preliminary studies 
revealed that the hydrolytic rate of degradation of NHS ester groups linked to PEG and 
PTMG diacids was too rapid for effective peptide coupling. As a result, peptide 
conjugation was conducted in an organic solvent in the presence of DMAp and Et3N. 
For such a reaction, an excess of peptide is typically used to ensure both ends of the 
target molecule react with free amine-terminated compounds; however, the high cost of 
synthesizing the biodegradable peptide sequence limits its availability.209 Instead, lysine 
was incorporated into the peptide sequence, GPQGIWGQGK, to create a bifunctional 
polymer. This enables polymer stoichiometry to dictate peptide-polyol conjugation, 
which promotes effective end capping. Following triblock synthesis, terminal amine 
groups generated from conjugation to the peptide sequence were further coupled to 
NHS-activated, ether-based carboxylic acid derivatives to form peptide-polyol 
multiblocks. These multiblocks were then reacted with EDA to form                      
amine-functionalized, biodegradable soft segments. 
3.2.1   Materials 
 NHS-activated PEG and PTMG diacids were prepared as previously described. 
4-(Dimethylamino) pyridine (DMAp), triethylamine (Et3N), ethylene diamine (EDA), 
dimethylformamide (DMF), and deuterated dimethyl sulfoxide (d6-DMSO) were 
obtained from Sigma-Aldrich and used as received. The biodegradable peptide sequence 
(GPQGIWGQGK) was synthesized at the Baylor Protein Chemistry Core Laboratory 
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where it was generated on an ABI 433A solid-phase synthesizer and analyzed by reverse 
phase HPLC and mass spectroscopy. Once received, peptide sequences were stored at    
-80°C and then lyophilized prior to use. The Kaiser test kit was obtained from Fluka 
Chemical. 
3.2.2   Methods 
PEG and PTMG triblocks were prepared by nucleophilic substitution of       
NHS-activated diacids with primary amine groups of bifunctional peptide sequences in 
the presence of DMAp and Et3N, Figure 3.3. NHS-activated PEG or PTMG diacids 
were dissolved in DMF and then added drop wise to a solution of DMAp, Et3N, and the 
biodegradable peptide sequence while stirring. After addition, the mixture was stirred at 
room temperature under nitrogen until NHS ester groups were no longer reactive (FTIR 
samples were taken periodically to monitor absorption peaks indicative of NHS 
activation). Solutions were then diluted with distilled water and peptide-polyol 
conjugates were retrieved with ultrafiltration through a solvent-resistant stirred cell. 
Molecular weight retention of ultrafiltration membranes was ~1000 g/mol. PEG and 
PTMG-based triblocks were then re-dissolved with distilled water, stored at -80°C, and 
subsequently lyophilized for characterization.  
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Figure 3.3. Synthesis of PEG triblocks in the presence of DMAp and Et3N.  
 
Upon successful conjugation, terminal amine groups of PEG and PTMG-based 
triblocks were reacted with NHS-activated carboxylic acid derivatives to form     
peptide-polyol multiblocks. PEG or PTMG triblocks were first dissolved in DMF and 
then added drop wise to a solution of DMAp, Et3N, and their respective NHS-activated 
carboxylic acid derivative while stirring. After addition, the mixture was stirred at room 
temperature under nitrogen until NHS ester groups remained stable (FTIR samples were 
taken periodically to monitor absorption peaks indicative of NHS activation). Excess 
EDA was then added to the solution to functionalize multiblocks with primary amine 
end groups, Figure 3.4. Solutions were then diluted with distilled water and        
peptide-polyol conjugates were retrieved with ultrafiltration through a solvent-resistant 
stirred cell. PEG and PTMG-based multiblocks were then re-dissolved with distilled 
water, stored at -80°C, and subsequently lyophilized for characterization. Infrared 
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spectroscopic analysis was performed on a Bruker TENSOR 27 spectrometer to confirm 
peptide conjugation. A Kaiser test kit was used to verify the presence of free primary 
amine groups, as indicated by a color shift from yellow to a dark blue/purple hue.       
1H-NMR spectroscopy was also used to verify peptide conjugation, but due to low 




Figure 3.4. Synthesis of amine-functionalized PEG multiblocks.  
 
3.2.3    Results 
Synthesis of PEG (1000) triblock  
NHS-PEG (1000)-NHS (7.76 mg, 0.0056 mmol), peptide (11.5 mg, 0.0117 
mmol), DMAp (2.72 mg, 0.0223 mmol), and Et3N (3.41 µL, 0.0245 mmol) were reacted 
as previously described. In this way, PEG (1000) triblock was obtained as a white 
powder (2.32 mg, 13% yield). Successful conjugation was confirmed with FTIR 
spectroscopy based on the generation of a significant amide peak (1660 cm-1, C=O) 
indicative of the peptide backbone, Figure 3.5. In addition, the carbonyl peak at 1730 
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cm-1 attenuated due to the loss of carboxylic acid groups. The Ninhydrin assay turned 
purple, indicating free amine groups are present. 1H-NMR (δ, ppm): 0.6-0.9 (12H,          
-CH3), 1.5-2.1 (12H, -CH2-), 1.7-1.9 (2H, -CH-), 1.7-2.3 (24H, -CH2CH-), 2.1-2.7 (16H, 
-CH2CO-), 2.9-3.1 (4H, -CH2NHCO-), 3.64 (m, 85H, -CH2O-), 3.6-3.9 (16H,                  
-NHCH2CO-), 4.1-4.3 (4H, -NCH2-), 4.1-4.6 (10H, -NHCH-), 4.2-4.4 (4H, -CH2OCO-), 
4.4-4.6 (2H, -NCH-), 6.7-6.9 (8H, NH2CO-), 6.9-7.4 (10H, =CH-), 7.1-8.5 (18H,            
-NHCO-), 9.3-9.5 (2H, -NH-). 
 
 
Figure 3.5. FTIR spectra of PEG (1000) triblock synthesis. 
 
Synthesis of PEG (2000) triblock  
NHS-PEG (2000)-NHS (13.32 mg, 0.0056 mmol), peptide (11.5 mg, 0.0117 
mmol), DMAp (1.36 mg, 0.0111 mmol), and Et3N (1.71 µL, 0.0122 mmol) were reacted 
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as previously described. In this way, PEG (2000) triblock was obtained as a yellow 
powder (11.25 mg, 49% yield). Successful conjugation was confirmed with FTIR 
spectroscopy based on the generation of a significant amide peak (1662 cm-1, C=O) 
indicative of the peptide backbone, Figure 3.6. In addition, the carbonyl peak at 1730 
cm-1 attenuated due to the loss of carboxylic acid groups. The Ninhydrin assay turned 
purple, indicating free amine groups are present. 1H-NMR (δ, ppm): 0.6-0.9 (12H,          
-CH3), 1.5-2.1 (12H, -CH2-), 1.7-1.9 (2H, -CH-), 1.7-2.3 (24H, -CH2CH-), 2.1-2.7 (16H, 
-CH2CO-), 2.9-3.1 (4H, -CH2NHCO-), 3.64 (m, 176H, -CH2O-), 3.6-3.9 (16H,                
-NHCH2CO-), 4.1-4.3 (4H, -NCH2-), 4.1-4.6 (10H, -NHCH-), 4.2-4.4 (4H, -CH2OCO-), 
4.4-4.6 (2H, -NCH-), 6.7-6.9 (8H, NH2CO-), 6.9-7.4 (10H, =CH-), 7.1-8.5 (18H,            
-NHCO-), 9.3-9.5 (2H, -NH-). 
 
 
Figure 3.6. FTIR spectra of PEG (2000) triblock synthesis. 
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Synthesis of PTMG (1000) triblock  
NHS-PTMG (1000)-NHS (7.76 mg, 0.0056 mmol), peptide (11.5 mg, 0.0117 
mmol), DMAp (5.44 mg, 0.0445 mmol), and Et3N (6.82 µL, 0.0490 mmol) were reacted 
as previously described. In this way, PTMG (1000) triblock was obtained as a white 
powder (2.22 mg, 13% yield). Successful conjugation was confirmed with FTIR 
spectroscopy based on the generation of a significant amide peak (1658 cm-1, C=O) 
indicative of the peptide backbone, Figure 3.7. In addition, the carbonyl peak at 1735 
cm-1 attenuated due to the loss of carboxylic acid groups. The Ninhydrin assay turned 
purple, indicating free amine groups are present. 1H-NMR (δ, ppm): 0.6-0.9 (12H,          
-CH3), 1.5-2.1 (67H, -CH2-), 1.7-1.9 (2H, -CH-), 1.7-2.3 (24H, -CH2CH-), 2.1-2.7 (16H, 
-CH2CO-), 2.9-3.1 (4H, -CH2NHCO-), 3.41 (m, 51H, -CH2O-), 3.6-3.9 (16H,                  
-NHCH2CO-), 4.0-4.2 (4H, -CH2OCO-), 4.1-4.3 (4H, -NCH2-), 4.1-4.6 (10H, -NHCH-), 
4.4-4.6 (2H, -NCH-), 6.7-6.9 (8H, NH2CO-), 6.9-7.4 (10H, =CH-), 7.1-8.5 (18H,            




Figure 3.7. FTIR spectra of PTMG (1000) triblock synthesis. 
 
Synthesis of PEG (1000) multiblock  
PEG (1000) triblock (1.5 mg, 0.000479 mmol), NHS-PEG (1000)-NHS (1.4 mg, 
0.001005 mmol), DMAp (0.47 mg, 0.00383 mmol), Et3N (0.59 µL, 0.00421 mmol), and 
EDA (0.19 µL, 0.00287 mmol) were reacted as previously described. In this way, PEG 
(1000) multiblock was obtained as a clear solid (0.51 mg, 19% yield). Successful 
conjugation was confirmed with FTIR spectroscopy based on the shift in the relative 
heights of amide (1531 cm-1, C-N) and ether (1100 cm-1, -C-O-C-) peaks, Figure 3.8 




Figure 3.8. FTIR spectra of amine-functionalized PEG (1000) multiblock synthesis. 
 
Synthesis of PEG (2000) multiblock  
PEG (2000) triblock (5.8 mg, 0.0014 mmol), NHS-PEG (2000)-NHS (7.05 mg, 
0.0029 mmol), DMAp (1.37 mg, 0.0112 mmol), Et3N (1.72 µL, 0.0123 mmol), and 
EDA (0.56 µL, 0.008 mmol) were reacted as previously described. In this way, PEG 
(2000) multiblock was obtained as a white powder (5.47 mg, 46% yield). Successful 
conjugation was confirmed with FTIR spectroscopy based on the shift in the relative 
heights of amide (1531 cm-1, C-N) and ether (1100 cm-1, -C-O-C-) peaks, Figure 3.9. 




Figure 3.9. FTIR spectra of amine-functionalized PEG (2000) multiblock synthesis. 
 
Synthesis of PTMG (1000) multiblock  
PTMG (1000) triblock (0.85 mg, 0.00027 mmol), NHS-PTMG (1000)-NHS 
(0.79 mg, 0.00057 mmol), DMAp (0.27 mg, 0.00217 mmol), Et3N (0.33 µL, 0.00239 
mmol), and EDA (0.109 µL, 0.00163 mmol) were reacted as previously described. In 
this way, PTMG (1000) multiblock was obtained as a white powder (0.46 mg, 30% 
yield). Successful conjugation was confirmed with FTIR spectroscopy based on the shift 
in the relative heights of amide (1529 cm-1, C-N) and ether (1110 cm-1, -C-O-C-) peaks, 




Figure 3.10. FTIR spectra of amine-functionalized PTMG (1000) multiblock synthesis. 
 
The results of FTIR and NMR analysis revealed that all polyols were 
successfully conjugated to biodegradable peptide sequences, as indicated by the 
generation of significant amide peaks. Due to such low concentrations of peptide-polyol 
conjugates, as well as hydrogen bonding, quantitative analysis could not be performed 
with NMR spectroscopy; however, changes in the relative absorbance of specific peaks 
between FTIR spectra can be used to provide a qualitative measure of conjugation. For 
this study, the absorbance at 1730 cm-1 indicating the presence of carboxylic acid and 
ester groups was investigated for triblock syntheses. With limited conjugation, this 
absorbance peak should be of similar height to what it was in the spectrum for its 
respective diacid. As conjugation increases, this peak should attenuate until the 
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remaining contributions are solely from the presence of ester linkages. For all      
peptide-polyol-triblocks, this peak was reduced by approximately 50%, indicating 
significant conjugation. For multiblock syntheses, the relative ratio of amide peaks with 
respect to internal reference ether peaks was examined. A reduction in the relative height 
of the amide peak at 1531 cm-1 by roughly 50% was observed for all polymer samples, 
indicating successful multiblock formation. 
3.3  Polyurea Synthesis 
 Following synthesis of ether-based soft segments, terminal amine groups 
generated by functionalization with EDA can react with free isocyanate groups to form 
stable urea linkages. Similar to polyurethanes, polyurea synthesis is a step-growth 
polymerization in which bifunctional molecules react to produce a linear chain of 
monomers.106 Polyureas can be synthesized via a “one-step” process, in which all 
reagents are mixed at once, or a multistep synthesis. Segmented block copolymers are 
typically generated using a two step synthesis, referred to as the prepolymer method. In 
the first step, the soft segment is stirred with excess diisocyanate to form a prepolymer. 
The prepolymer is then chain extended with a low molecular weight diol or diamine to 
increase molecular weight and form a block copolymer. This method imparts greater 
control over the chemistry of the reaction, influencing the structure, physical properties, 
and processability of the final product.106 
 Because of these advantages, the two-step method is the favored strategy to 
synthesize segmented block copolymers for biomedical applications. For polyurethane 
syntheses, soft segment diols are typically added drop wise to excess diisocyanate in the 
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presence of an organo-tin catalyst and at elevated temperature.136, 141, 232-238 Shortly 
thereafter, the chain extender is added to the mixture, and FTIR spectroscopy is used to 
monitor the presence of free isocyanate groups to verify full polymerization. Because of 
the relatively high NCO-reactivity of primary amines compared to secondary hydroxyl 
groups, polyurea formation can predominate at room temperature in non-catalyzed 
systems.136, 234, 239, 240 The exceptionally high reactivity of primary amine groups also 
limits side reactions with water that affect the desired chemistry of the final product. A 
limitation of polyurea synthesis is the risk of biuret formation, in which secondary amine 
groups of urea linkages react with free isocyanate groups, effectively cross-linking the 
polymer. To prevent this, polyurea synthesis can be run at lower temperature to inhibit 
biuret formation. Overall, urea-based segmented block copolymers were selected for this 
application due to their relative ease of synthesis and because polyureas demonstrate 
higher mechanical properties than polyurethanes due to bidentate hydrogen bonding of 
urea linkages. This is especially important for the development of a biomaterial for 
ligament tissue engineering.128  
3.3.1   Materials 
 Amine-functionalized soft segments were prepared as previously described and 
dried 24 hours at 80°C under vacuum prior to use. Hexamethylene diisocyanate (HDI) 
was obtained from Fluka Analytical and used as received. Ethylene diamine (EDA) and 
diethyl ether were obtained from Sigma-Aldrich and used as received. 
Dimethylacetamide (DMAc) was obtained from Sigma-Aldrich and dried over 4Å 
molecular sieves 24 hours prior to use.  
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3.3.2   Methods 
 In the current study, amine-functionalized multiblocks and ether-based control 
soft segments were reacted with excess HDI and EDA to develop a series of linear 
polyurea elastomers, Figure 3.11. All polymerizations were carried out in a Labconco 
Controlled Atmosphere glove box containing dry nitrogen gas. Soft segments were first 
dissolved in DMAc and then added drop wise to an HDI solution while stirring. After 30 
minutes, EDA solution was added and the mixture was stirred at room temperature. The 
reaction was allowed to proceed until the NCO peak (~2270 cm-1) disappeared in the IR 
spectrum. For PEG and PTMG control polyurea syntheses, final products were 
precipitated for ten minutes from excess diethyl ether or aqueous KCL solution (10:1) 
that had been cooled in a salt ice bath. PEG and PTMG-based polyureas were then 
retrieved with vacuum aspiration and subsequently dried in a vacuum oven overnight. 
Peptide-based polyurea solutions were diluted with distilled water and then retrieved via 
ultrafiltration through a solvent-resistant stirred cell. Resulting peptide-based polyureas 
were then re-dissolved with distilled water, stored at -80°C, and subsequently 
lyophilized for characterization. Infrared spectroscopic analysis was performed on a 
Bruker TENSOR 27 spectrometer to confirm urea formation. 
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Figure 3.11. Synthesis of ether-based polyureas using PEG diamine. 
 
3.3.3   Results 
Synthesis of PEG (6000) control polyureas  
3 – 1 – 2: PEG (6000) diamine (0.23 g, 0.0366 mmol), HDI (18.22 µL, 0.1134 
mmol), and EDA (4.90 µL, 0.0732 mmol) were reacted as previously described. In this 
way, PEG (6000) polyurea (3-1-2) was obtained as a brittle, white solid (0.19 g, 76% 
yield). 5 – 1 – 4: PEG (6000) diamine (0.50 g, 0.0795 mmol), HDI (65.17 µL, 0.4056 
mmol), and EDA (21.32 µL, 0.3182 mmol) were reacted as previously described. In this 
way, PEG (6000) polyurea (5-1-4) was obtained as a flaky, clear solid (0.48 g, 82% 
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yield). Urea formation (1632 cm-1, hydrogen-bonded C=O; 3320 cm-1, hydrogen-bonded 
N-H) was confirmed with FTIR spectroscopy, Figure 3.12. 
 
 
Figure 3.12. FTIR spectral comparison of PEG (6000) control polyureas. 
 
Synthesis of PEG (10000) control polyureas 
3 – 1 – 2: PEG (10000) diamine (0.10 g, 0.0097 mmol), HDI (4.84 µL, 0.0301 
mmol), and EDA (1.303 µL, 0.0194 mmol) were reacted as previously described. In this 
way, PEG (10000) polyurea (3-1-2) was obtained as a white powder (57.4 mg, 54% 
yield). 5 – 1 – 4: PEG (10000) diamine (0.11 g, 0.0107 mmol), HDI (8.76 µL, 0.0545 
mmol), and EDA (2.87 µL, 0.0428 mmol) were reacted as previously described. In this 
way, PEG (10000) polyurea (5-1-4) was obtained as a white powder (77.9 mg, 64% 
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yield). Urea formation (1632 cm-1, hydrogen-bonded C=O; 3320 cm-1, hydrogen-bonded 
N-H) was confirmed with FTIR spectroscopy, Figure 3.13. 
 
 
Figure 3.13. FTIR spectral comparison of PEG (10000) control polyureas. 
 
Synthesis of PTMG (5600) control polyureas 
3 – 1 – 2: PTMG (5600) diamine (0.10 g, 0.0177 mmol), HDI (8.83 µL, 0.055 
mmol), and EDA (2.38 µL, 0.0355 mmol) were reacted as previously described. In this 
way, PTMG (5600) polyurea (3-1-2) was obtained as a yellow, waxy solid (74.6 mg, 
67% yield). 5 – 1 – 4: PTMG (5600) diamine (0.10 g, 0.0177 mmol), HDI (14.53 µL, 
0.0904 mmol), and EDA (4.75 µL, 0.071 mmol) were reacted as previously described. 
In this way, PTMG (5600) polyurea (5-1-4) was obtained as a yellow, waxy solid (88.4 
mg, 74% yield). Urea formation (1701 cm-1, free C=O; 1633 cm-1, hydrogen-bonded 
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Figure 3.14. FTIR spectral comparison of PTMG (5600) control polyureas. 
 
Synthesis of PEG (1000) multiblock polyureas 
3 – 1 – 2:  PEG (1000) multiblock (0.20 mg, 0.0358 µmol), HDI (0.0178 µL, 
0.1109 µmol), and EDA (0.0048 µL, 0.0716 µmol) were reacted as previously 
described. 5 – 1 – 4: PEG (1000) multiblock (0.20 mg, 0.0358 µmol), HDI (0.0293 µL, 
0.1825 µmol), and EDA (0.0096 µL, 0.1432 µmol) were reacted as previously 
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described. Urea formation (1691 cm-1, free C=O; 1635 cm-1, hydrogen-bonded C=O; 
3328 cm-1, hydrogen-bonded N-H) was confirmed with FTIR spectroscopy, Figure 3.15. 
 
 
Figure 3.15. FTIR spectral comparison of PEG (1000) multiblock polyureas. 
 
Synthesis of PEG (2000) multiblock polyureas 
3 – 1 – 2:  PEG (2000) multiblock (1.0 mg, 0.116 µmol), HDI (0.058 µL, 0.361 
µmol), and EDA (0.0156 µL, 0.233 µmol) were reacted as previously described.            
5 – 1 – 4: PEG (2000) multiblock (1.0 mg, 0.116 µmol), HDI (0.095 µL, 0.594 µmol), 
and EDA (0.0312 µL, 0.466 µmol) were reacted as previously described. Urea formation 
(1635 cm-1, hydrogen-bonded C=O; 3327 cm-1, hydrogen-bonded N-H) was confirmed 




Figure 3.16. FTIR spectral comparison of PEG (2000) multiblock polyureas. 
 
Synthesis of PTMG (1000) multiblock polyureas 
3 – 1 – 2:  PTMG (1000) multiblock (0.18 mg, 0.0322 µmol), HDI (0.016 µL, 
0.1 µmol), and EDA (0.0043 µL, 0.0644 µmol) were reacted as previously described.    
5 – 1 – 4: PTMG (1000) multiblock (0.18 mg, 0.0322 µmol), HDI (0.0264 µL, 0.164 
µmol), and EDA (0.0086 µL, 0.129 µmol) were reacted as previously described. Urea 
formation (1689 cm-1, free C=O; 1635 cm-1, hydrogen-bonded C=O; 3328 cm-1, 




Figure 3.17. FTIR spectral comparison of PTMG (1000) multiblock polyureas. 
 
FTIR spectral analysis revealed the presence of characteristic urea peaks (~1630 
cm-1, hydrogen-bonded C=O; ~1690 cm-1, free C=O; ~3328 cm-1, hydrogen-bonded     
N-H) among all polymer samples. FTIR spectra of PEG-based control polyureas 
predominantly consisted of hydrogen-bonded urea peaks, indicating a relatively high 
degree of phase separation. PTMG-based control polyureas also demonstrated a 
significant amount of hydrogen-bonded urea peaks, although free carbonyl peaks were 
also observed. The relative height of these peaks, with respect to the internal reference 
ether peak, is proportional to the hard segment content. Therefore, these peaks are 
elevated at higher hard to soft segment ratios. This trend was observed in the FTIR 
spectra for all control and multiblock polyureas. Similar to PEG-based control 
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polyureas, FTIR spectra of PEG (2000) multiblock polyureas revealed the presence of 
hydrogen-bonded urea peaks that were elevated at higher hard to soft segment ratios. 
The FTIR spectrum for PEG (1000) multiblock polyurea (5-1-4) also demonstrated 
considerable hydrogen-bonded urea formation, although free carbonyl peaks were 
detected. This free carbonyl peak was expressed more significantly in the FTIR 
spectrum for PEG (1000) multiblock polyurea (3-1-2), indicating a degree of phase 
mixing. Finally, similar to PTMG-based control polyureas, the FTIR spectra for PTMG 
(1000) multiblock polyureas predominantly consisted of hydrogen-bonded urea peaks, 
although free carbonyl peaks were also observed. 
3.4  Conclusions 
Integration of biomimetic peptide sequences into the design of novel 
biomaterials is a useful strategy to achieve desired cell behavior. In the current study, 
synthetic routes were developed to conjugate collagenase-sensitive peptide sequences to 
ether-based polyols to form biodegradable multiblocks. Successful protein conjugation 
of all desired NHS-activated carboxylic acid derivatives was confirmed with FTIR and 
NMR analysis. Changes in the relative absorbance of specific peaks between FTIR 
spectra were used as a qualitative measure of conjugation. Furthermore, the Ninhydrin 
assay verified the presence of free amine groups, which are needed for subsequent 
syntheses. Based on these results, ether-based triblocks were further reacted with     
NHS-activated carboxylic acid derivatives and then EDA to form amine-functionalized, 
biodegradable multiblocks. Again, FTIR analysis confirmed successful multiblock 
formation, and the Ninhydrin assay verified the presence of free amine groups.  
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Amine-functionalized, multiblock soft segments were then reacted with excess 
HDI and EDA to develop a series of linear polyurea elastomers. Successful urea 
formation was confirmed with FTIR analysis. As expected, relative absorbances of urea 
linkages with respect to internal reference ether peaks were elevated at higher hard to 
soft segment ratios. Synthesis of polyureas was also demonstrated by changes in the 
physical properties of all polymer samples, including an increase in viscosity as well as 
reduced solubility that results from hydrogen bonding. Further characterization is 
needed to verify molecular weight using size exclusion chromatography.  
The results of the current study indicate successful synthesis of cell-responsive, 
biodegradable polyureas. By altering soft segment chemistry and polyol molecular 
weight, as well as the hard to soft segment content, a library of polyurea elastomers was 
developed. The next step will be to further characterize these polymers to elucidate key 
structure-property relationships. To do so, dynamic mechanical analysis (DMA) can be 
used in conjunction with FTIR spectroscopy to determine the effect of composition on 
microphase-separated morphology. The tensile properties of these polyureas can then be 
determined using an Instron testing machine. Finally, the effect of polymer chemistry on 
the rate of enzyme-mediated degradation must also be investigated. Ultimately, 
understanding such relationships will be critical for the development of an improved 








 In this study, a library of cell-responsive, biodegradable polyureas was 
synthesized to elucidate key structure-property relationships for the development of a 
tissue engineered ligament. The first step was to functionalize ether-based polyols with 
reactive end groups necessary for facile coupling to collagen-derived peptide sequences. 
PEG and PTMG of varying molecular weights were reacted with succinic anhydride to 
modify these polyols with carboxylic acid end groups. Functionalization was confirmed 
with FTIR spectroscopy based on the generation of characteristic ester peaks within the 
carbonyl region at ~1730 cm-1. The relative height of such ester peaks with respect to the 
internal reference ether (-C-O-C-) peak corresponded with the molecular weight of each 
polyol. In addition, the appearance of methylene (-CH2OCO-) proton peaks at 4.25 ppm 
and succinate (-CH2COO-) peaks at 2.64 ppm in all NMR spectra indicated successful 
syntheses. The peak areas for these chemical shifts showed that functionalization of all 
candidate polyols was greater than 90%. 
 Carboxylic acid derivatives of PEG and PTMG soft segments were then 
activated with NHS in the presence of DCC to generate superior leaving groups for 
peptide coupling. Successful NHS activation of all polymer samples was indicated by 
the appearance of typical NHS carbonyl peaks at ~1810 cm-1 and ~1780 cm-1 in FTIR 
spectra. Formation of NHS ester groups was further demonstrated by corollary increases 
in all ester peaks at 1730 cm-1. Similar to carboxylic acid functionalized polyols, the 
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relative height of these NHS carbonyl peaks corresponded with the molecular weight of 
each polymer. NMR spectra of all PEG and PTMG-based NHS ester derivatives showed 
proton peaks of succinimide at 2.84 ppm. In addition, proton peaks at 2.64 ppm shifted 
to 2.78 ppm and 2.96 ppm upon activation with NHS due to changes in the 
electronegativity of succinate groups. A singlet at 2.71 ppm represented the presence of 
unreacted NHS that cannot be completely removed using typical purification methods. 
 Following activation with NHS, carboxylic acid derivatives of higher molecular 
weight (PEG: 6000, 10000 g/mol) were reacted with excess EDA in the presence of 
DMAp and Et3N to form amine-functionalized, control soft segments for subsequent 
polyurea syntheses. Successful functionalization was determined by the generation of 
characteristic amide peaks among FTIR spectra between 1625 and 1640 cm-1, which are 
also indicative of hydrogen bonding. Again, the relative height of these amide peaks 
with respect to the internal reference ether peak was dependent on the molecular weight 
of the polyol. Hydrogen bonding was also found to shift the ester carbonyl peak of  
PEG-based derivatives to ~1685 cm-1. Because of hydrogen bonding, NMR 
spectroscopy could not be used as a quantitative measure of functionalization due to 
variations in the relaxation time of such proton peaks.  
A higher molecular weight derivative of PTMG was not commercially available, 
and so PTMG (1000) was first functionalized with excess EDA, and then used to end 
cap PTMG (2900) diacid to form a PTMG-based control soft segment of comparable 
molecular weight. The FTIR spectrum for PTMG (1000) diamine showed an amide peak 
at ~1660 cm-1; however, unlike PEG (6000) and PEG (10000) diamine, characteristic 
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amide and ester peaks were not significantly affected by hydrogen bonding. Upon 
successful functionalization with EDA, PTMG (1000) diamine was reacted with PTMG 
(2900) diacid in the presence of DMAp and Et3N to form PTMG (5600) diamine. The 
FTIR spectrum for PTMG (5600) diamine showed a reduction in the relative heights of 
amide and ester peaks with respect to the internal reference ether peak, as compared to 
the FTIR spectra for PTMG (1000) diamine and PTMG (2900) diacid. This resulted 
from a decrease in the amount of functional end groups available after successful 
synthesis, as well as an overall reduction in the relative amount of particular functional 
groups due to increased molecular weight. Unlike PTMG (1000) diamine, the FTIR 
spectrum for PTMG (5600) diamine displayed characteristic peaks of both free and 
hydrogen bonded amide and ester peaks. This suggests that the low molecular weight of 
PTMG (1000) diamine inhibited hydrogen bonding, and not its polyol chemistry. 
Following FTIR analyses, Ninhydrin assays confirmed the presence of free amine 
groups in all PEG and PTMG-based control soft segments, which are necessary for 
subsequent polyurea syntheses. 
  Similar to amine-functionalized, control soft segments, NHS-activated 
carboxylic acid derivatives of lower molecular weight (PEG: 1000, 2000 g/mol; PTMG: 
1000 g/mol) were reacted with collagen-derived peptide sequences in the presence of 
DMAp and Et3N to form peptide-polyol conjugates. First, NHS ester derivatives were 
end capped with peptide sequences to form peptide-polyol-peptide triblocks. Successful 
conjugation was verified with FTIR and NMR spectroscopy, as indicated by the 
generation of significant amide peaks at ~1660 cm-1 and between 7.1 and 8.2 ppm, 
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respectively. Due to such low concentrations of peptide-polyol conjugates, as well as 
hydrogen bonding, NMR spectroscopy could not be used for quantitative analysis. 
Instead, changes in the relative absorbance at 1730 cm-1 were used as a qualitative 
measure of conjugation for all triblock syntheses. With limited conjugation, this 
absorbance peak should be similar to what it was in the spectrum for its respective 
diacid, with carboxylic acid and ester groups contributing to its effective height. As 
conjugation increases, this peak should attenuate until the remaining contributions are 
solely from the presence of ester linkages. For all peptide-polyol-triblocks, this peak was 
reduced by approximately 50%, indicating significant conjugation. Following FTIR 
analysis, Ninhydrin assays verified the presence of free amine groups among PEG and 
PTMG-based triblocks. For multiblock syntheses, the relative ratio of amide peaks with 
respect to internal reference ether peaks was examined. A significant reduction in the 
relative height of the amide peak at 1531 cm-1 was observed for all polymer samples, 
indicating successful multiblock formation. Again, Ninhydrin assays confirmed the 
presence of free amine groups of all amine-functionalized multiblocks that are necessary 
for polyurea synthesis.  
 Amine-functionalized control and multiblock soft segments were then reacted 
with HDI and EDA to form linear polyurea elastomers. Successful urea formation was 
determined based on the generation of characteristic urea peaks (~1630 cm-1,   
hydrogen-bonded C=O; ~1690 cm-1, free C=O; ~3328 cm-1, hydrogen-bonded N-H) in 
the FTIR spectra of these polymers. The spectra for PEG-based control polyureas 
predominantly consisted of hydrogen-bonded urea peaks, indicating a relatively high 
 79 
degree of phase separation. The relative height of these peaks, with respect to the 
internal reference ether peak, is proportional to the hard segment content. Therefore, 
these peaks are elevated at higher hard to soft segment ratios. This trend was observed in 
the FTIR spectra for all candidate polyureas.  
PTMG-based control polyureas also demonstrated a significant amount of 
hydrogen-bonded urea peaks; however, free carbonyl peaks were present. Formation of 
these peaks indicates that not all urea linkages separated into semi-crystalline, hard 
domains, referred to as phase mixing. The degree of phase separation is dictated by the 
reduction of interfacial energy between hard and soft segments, and phase mixing is 
enhanced by decreases in this free surface energy.241-243 PTMG is more hydrophobic 
than PEG, and so it has less surface energy.244 Therefore, the presence of free carbonyl 
peaks in the FTIR spectra of PTMG-based polyureas resulted from their hydrophobic 
nature. Regardless, a relatively high degree of phase separation was still achieved. 
Furthermore, increased hard segment content was found to increase the relative ratio of 
hydrogen-bonded to free urea peaks, thus enhancing the degree of phase separation. 
 Unlike the control polyureas, the FTIR spectrum for PEG (1000) multiblock 
polyurea (3-1-2) displayed dominant free carbonyl peaks, indicating a relatively low 
degree of phase separation. In this instance, the use of such a low molecular weight 
polyol combined with the incorporation of bulky peptide sequences prevented the 
formation of semi-crystalline, hard domains.245 However, by increasing the hard to soft 
segment ratio, formation of hard domains became more favorable due to the increased 
presence of symmetrical HDI and EDA-based segments.246 This trend was demonstrated 
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in the FTIR spectrum for PEG (1000) multiblock polyurea (5-1-4), which showed a 
dominant hydrogen-bonded urea peak at 1635 cm-1. FTIR spectra for PEG (2000) 
multiblock polyureas (3-1-2; 5-1-4) did not reveal a free carbonyl peak, but only 
significant hydrogen-bonded urea peaks. This is due to increased flexibility of the soft 
segment resulting from the use of a slightly higher molecular weight polyol.247 Similar 
to the control polyureas, the relative height of these urea peaks increased at higher hard 
to soft segment ratios.  
The FTIR spectra for PTMG (1000) multiblock polyureas also predominantly 
consisted of hydrogen-bonded urea peaks, although free carbonyl peaks were detected. 
As with PTMG-based control polyureas, the generation of these peaks was reflective of 
the soft segment chemistry of these polyureas, and the relative ratio of hydrogen-bonded 
to free urea peaks increased at higher hard to soft segment ratios. It is important to note 
that, unlike PEG (1000) multiblock polyurea (3-1-2), the FTIR spectrum for PTMG 
(1000) multiblock polyurea (3-1-2) did not show a significant free carbonyl peak. This 
suggests that, because of its hydrophobic nature, PTMG is more conducive to the 
formation of semi-crystalline, hard domains than PEG in the presence of such large 
peptide sequences at low hard segment contents. Still, additional experiments are 
necessary to further elucidate this structure-property relationship. Overall, a library of 
linear polyurea elastomers was successfully developed using the aforementioned 
synthetic strategies, and these polymers feature a relatively high degree of phase 
separation. 
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 As stated previously, the microphase-separated morphology of polyurea 
elastomers dictates their unique deformation behavior. This behavior is the foundation 
for understanding key structure-property relationships. In addition to FTIR 
spectroscopy, DMA is needed to further monitor the effect of polymer composition on 
phase separation of all candidate polyureas. Instron testing can then be used to determine 
the tensile properties of these polymers. In addition to mechanical testing,           
enzyme-mediated degradation studies are needed to determine the effect of phase 
separation on the rate of degradation. Based on these results, polyurea chemistry can be 
tailored to alter the degree of phase separation, and thus obtain specific performance 
properties. Investigation of structure-property relationships will enable the rational 
design of an improved biomaterial for ligament tissue engineering. 
 The first step in the rational design of a biodegradable material for tissue 
engineering is to determine the effect of system-responsive degradation on its 
mechanical properties. To do this, mechanical testing of all candidate polyureas is 
needed at specific points of degradation. By utilizing elucidated structure-property 
relationships, polyurea chemistry can be tailored to synthesize control specimens with 
mechanical properties comparable to these stages of degradation. Cells may then be 
seeded onto control polyurea scaffolds to observe the effect of these mechanical 
properties on cell behavior.248, 249 Based on these results, biodegradable polyurea 
elastomers can be designed so that scaffold degradation complements neotissue 
formation. Due to the versatility of the aforementioned synthetic routes, polyurea 
chemistry can be further modified as necessary to achieve this desired behavior. For 
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example, polyol molecular weight can be adjusted to modulate the relative concentration 
of enzyme-labile peptide sequences. PEG and PTMG-based derivatives can be utilized 
within the same system to modify the hydrophilicity of the soft segment, which would 
alter the degree of phase separation. Finally, additional peptide sequences, such as RGD, 
can be incorporated into enzyme-labile soft segments, which would not only provide 
cell-responsive degradation, but also increase cell adhesion.250 
 In order to conduct further experimentation, mass production of cell-responsive, 
biodegradable polyureas is needed. Currently, these polymers are developed in very 
small quantities, and as a result, the effective yields for these reactions are fairly low 
(~10-50%). Increasing the scale of production would improve these yields; however, due 
to the high cost to synthesize custom peptide sequences, this approach would not be cost 
effective. Recombinant strategies could be utilized instead of solid phase peptide 
synthesis, which would enable large-scale peptide synthesis at a reasonable cost.251-253 
Although synthesis of short peptide chains can be problematic with microbial systems, 
research is currently in progress to circumvent this issue. Fusion proteins are in 
development from which a short peptide sequence can be released and recovered.254, 255 
Through isolation and purification, a desired peptide sequence can thus be obtained.256, 
257
 These sequences can then be implemented into the synthesis of cell-responsive, 
biodegradable polyureas, allowing large-scale production of these polymers. 
 In addition to the development of an improved biomaterial for ACL 
reconstruction, synthetic strategies used to generate a library of cell-responsive, 
biodegradable polyureas can be utilized for a variety of other biomedical applications as 
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well. Similar to the current approach, enzyme-labile poly (urethane urea)s can be 
developed to create new structure-property models for bone or cardiovascular tissue 
engineering. A polymeric system that combines the tunability of segmented block 
copolymers with system-responsive degradation can also be used to achieve effective 
drug delivery.258, 259 Based on the versatility of the synthetic routes described above, 
enzyme-labile peptide sequences can be replaced with other sequences to produce an 
assortment of biomimetic materials. For instance, a peptide chromophore can be 
implemented into the design of a novel biomaterial and serve as an effective 
biosensor.260, 261 Carboxylic acid and amine functionalization of PTMG is of particular 
importance because, unlike PEG, functionalization of PTMG has not been                
well-established throughout the literature.186 As a result, the synthetic routes and 
purification techniques reported in this study can be adapted to utilize PTMG in various 
applications previously dominated by PEG. Overall, the synthesis of a library of        
cell-responsive, biodegradable polyureas will assist in the development of a tissue 
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1H-NMR spectrum of PEG (1000) diacid.  
 
1H-NMR spectrum of NHS-PEG (1000)-NHS. 
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1H-NMR spectrum of PEG (2000) diacid. 
 




1H-NMR spectrum of PEG (6000) diacid. 
 




1H-NMR spectrum of PEG (10000) diacid. 
 





1H-NMR spectrum of PTMG (1000) diacid. 
 




1H-NMR spectrum of PTMG (2900) diacid. 
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